

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 134 286 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

19.09.2001 Bulletin 2001/38

(21) Application number: **01302060.7**

(22) Date of filing: **06.03.2001**

(51) Int Cl.7: **C12N 15/57**, C12N 9/64,
C12N 5/10, C12N 1/21,
C07K 16/40, A61K 39/395,
C12Q 1/68, C12Q 1/37,
A61K 38/48

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: **14.03.2000 US 189244 P**

(71) Applicant: **Pfizer Products Inc.**

Groton, Connecticut 06340 (US)

(72) Inventors:

- **Buckbinder, Leonard**
Groton, Connecticut 06340 (US)

- **Mitchell, Peter Geoffrey**
Groton, Connecticut 06340 (US)
- **Wachtmann, Timothy Scott**
Groton, Connecticut 06340 (US)
- **Walsh, Roderick Thomas**
Sandwich, Kent CT13 9NJ (GB)

(74) Representative: **Hayles, James Richard et al**
Pfizer Limited,
Patents Department,
Ramsgate Road
Sandwich Kent CT13 9NJ (GB)

(54) **Adamts polypeptides, nucleic acids encoding them, and uses thereof**

(57) The present invention relates to a member of the family of proteins known as ADAMTS proteins, the new member being designated ADAMTS-J1. The invention also relates to polynucleotides encoding ADAMTS-

J1, antibodies to ADAMTS-J1, assays for studying the function of ADAMTS-J1, assays for determining agonists or antagonists of ADAMTS-J1, and to the use of ADAMTS-J1 polypeptides or polynucleotides in diagnostic, biotherapeutic, or gene therapy methods.

EP 1 134 286 A2

DescriptionField of Invention

[0001] The present invention relates to a member of the family of proteins known as ADAMTS.

Background Of The Invention

[0002] ADAMTS proteins exhibit characteristics of the ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain a thrombospondin domain (TS). The prototypic ADAMTS was identified in mouse, found to be expressed in heart and kidney and upregulated by proinflammatory stimuli (K. Kuno et al., *Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as a inflammation associated gene*, 272 Journal of Biological Chemistry 556 (January 1997). To date nine members are recognized by the HUGO database (<http://www.gene.ucl.ac.uk/users/hester/adamts>.) with sequence information available for all but two of these. Members of this family have the ability to degrade aggrecan, a high molecular weight proteoglycan which provides cartilage with important mechanical properties and which is lost during the development of arthritis.

[0003] Aggrecanase activity has been demonstrated for several ADAMTS proteins (See, e.g., M.D. Tortorella, *Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins*, 284 Science 1664 (June 1999); I. Abbaszade, *Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family*, 274 Journal of Biological Chemistry 23443 (August 1999)). In addition to aggrecanase activity, ADAMTS-4 was shown to cleave another proteoglycan, brevican, found predominately expressed in the central nervous system (Matthews et al., *Brain-enriched hyaluronan binding (BEHAB)/Brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member*, 275 Journal of Biological Chemistry 22695 (July 2000)). This activity was speculated to play a role in the invasiveness of glioma. Additional activities of ADAMTS-4 are proposed as its expression was induced in rat astrocytes treated with beta-amyloid, suggesting a role in Alzheimer's disease (Sato et al., *ADAMTS-4 is transcriptionally induced in beta-amyloid treated rat astrocytes*, 289 Neuroscience Letters 177 (2000)). Other ADAMTS proteins are reported to exhibit antiangiogenic (See, e.g. F. Vazquez et al., *METH-1, A human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with Angio-inhibitory activity*, 274 Journal of Biological Chemistry 23349 (August 1999)) and/or procollagen processing activities (A. Colige et al., *cDNA cloning and expression of bovine procollagen I N-proteinase: a new member of the superfamily of zinc-metalloproteinase with binding sites for cells and other matrix components*, 94 Proceedings of the National Academy of Sciences of the United States of America 2374 (March 1997)). Additional roles for ADAMTS-1 in fertility and organ development, particularly with respect to the urogenital system, were implicated by gene knock out in mice (Shindo et al" *ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function*, 105 Journal of Clinical Investigation 1345 (May 2000)).

[0004] ADAMTS proteins and ADAMTS protein agonists and antagonists have important therapeutic uses, including treatment of arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, diabetic shock, infertility and other diseases characterized by metalloproteinase activity and/or characterized by mammalian adamalysin activity.

Summary Of The Invention

[0005] This invention relates to a novel ADAMTS protein, designated ADAMTS-J1, and to related polynucleotides and polypeptides. The invention also relates to production of the protein and polypeptides and to related assays. The invention further relates to methods for identifying substrates of the protein, for identifying inhibitors or activators of the protein, and to the use of the polypeptides or polynucleotides of the invention in diagnostic, biotherapeutic, and gene therapy methods.

[0006] In particular, the invention relates to an isolated polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence having at least 80% identity to a nucleotide sequence encoding ADAMTS-J1 polypeptide of SEQ ID NO: 5, 6, 7 or 8, or a metalloproteinase, disintegrin domain, prodomain, or thrombospondin (TSP) domain thereof;

(b) a nucleotide sequence of at least 15 contiguous nucleotides that hybridizes under stringent conditions to the polynucleotide molecule of SEQ ID NO: 1, 2, 3 or 4; and

(c) the complement of the nucleotide sequence of (a) or (b).

Such an isolated polynucleotide molecule, can, for example, comprise DNA or RNA.

[0007] In one embodiment, the isolated polynucleotide is at least 80% identical to SEQ ID NO: 1, 2, 3, or 4, or a metalloproteinase, disintegrin domain, prodomain, or thrombospondin (TSP) domain thereof. In another embodiment the isolated polynucleotide encodes the ADAMTS-J1 polypeptide encoded by a sequence of SEQ ID NO: 1, 2, 3, or 4, or a metalloproteinase, disintegrin domain, prodomain, or thrombospondin (TSP) domain thereof. In a most preferred embodiment, the isolated polynucleotide comprises the ADAMTS-J1 polypeptide encoding sequence of SEQ ID NO: 1, 2, 3, or 4, or a metalloproteinase, disintegrin domain, prodomain, or thrombospondin (TSP) domain encoding sequence thereof.

[0008] In a further embodiment, the invention relates to a polypeptide encoded by the isolated polynucleotide molecule of the invention. For example, the ADAMTS-J1 polypeptide of the invention can comprise an amino acid sequence which is at least 80% identical to SEQ ID NO: 5, 6, 7, or 8 or an amino acid sequence of at least about 10 contiguous amino acids of ADAMTS-J1. In a preferred embodiment, the polypeptide comprises SEQ ID NO: 5, 6, 7, or 8, or a metalloproteinase, disintegrin domain, prodomain, or thrombospondin (TSP) domain thereof.

[0009] In another aspect, the invention relates to an expression system comprising a DNA or RNA molecule, wherein the expression system is capable of producing an ADAMTS-J1 polypeptide that comprises an amino acid sequence that has at least 80% identity with a polypeptide of SEQ ID NO: 5, 6, 7, or 8, or a metalloproteinase, disintegrin domain, prodomain, or thrombospondin (TSP) domain thereof, when said expression system is present in a compatible host cell. In one embodiment of this aspect of the invention, the expression system is capable of producing an ADAMTS-J1 polypeptide encoded by a polynucleotide of the invention.

[0010] In another aspect, the invention relates to a host cell that comprises the expression system of the invention.

[0011] In another aspect, the invention relates to a process for producing an ADAMTS-J1 polypeptide that comprises culturing a host cell of the invention under conditions sufficient for production of the polypeptide, and recovering the polypeptide from cell culture.

[0012] In another aspect, the invention relates to a process for producing a cell which produces an ADAMTS-J1 polypeptide comprising transforming or transfecting a host cell with an expression system of the invention such that the host cell, under appropriate culture conditions produces the ADAMTS-J1 polypeptide.

[0013] In another aspect, the invention relates to an antibody that is immunospecific for an ADAMTS-J1 polypeptide of the invention. The invention also relates to antagonists, agonists, and substrates of the polypeptide of the invention.

[0014] In a further aspect, the invention relates to a method for treating a subject in need of altering activity or expression of ADAMTS-J1 comprising administering to the subject a therapeutically effective amount of an agonist or antagonist of ADAMTS-J1.

[0015] In another aspect, the invention relates to a method for treating a subject in need of altering activity or expression of ADAMTS-J1 comprising administering to the subject a polynucleotide of the invention in order to alter said activity or expression. The invention also relates to a method for treating a subject in need of altering activity or expression of ADAMTS-J1 comprising administering to the subject a therapeutically effective amount of a polypeptide that competes with ADAMTS-J1 for its ligand, substrate, or receptor.

[0016] The invention also relates to a process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of ADAMTS-J1 in a subject comprising determining presence or absence of a mutation in a nucleotide sequence encoding ADAMTS-J1 in the genome of the subject. Alternately, the invention relates to a process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of ADAMTS-J1 in a subject comprising analyzing for presence or amount of ADAMTS-J1 expression in a sample derived from the subject.

[0017] In another aspect, the invention relates to a method for identifying compounds which antagonize ADAMTS-J1 comprising:

(a) contacting a candidate compound with cells expressing an ADAMTS-J1 polypeptide of the invention, or with cell membranes from cells expressing the ADAMTS-J1 polypeptide, or the media conditioned by cells expressing the polypeptide, or a purified composition of said polypeptide; and

(b) determining inhibition of an ADAMTS-J1 activity.

[0018] In an alternate embodiment, the invention relates to a method for identifying compounds which agonize AD-

AMTS-J1 comprising:

- (a) contacting a candidate compound with cells expressing an ADAMTS-J1 polypeptide of the invention, or with cell membranes from cells expressing the polypeptide, or media conditioned by cells expressing the polypeptide, or a purified composition of the polypeptide; and
- (b) determining stimulation of an ADAMTS J1 activity.

[0019] In an further embodiment, the invention relates to a method for identifying compounds which bind to ADAMTS-J1 comprising:

- (a) contacting a candidate compound with cells expressing an ADAMTS-J1 polypeptide of the invention, or with cell membranes from cells expressing the polypeptide, or the media conditioned by cells expressing the polypeptide, or a purified composition of the polypeptide; and
- (b) determining binding of the candidate compound to the polypeptide.

[0020] The invention also relates to a method for detecting a polynucleotide encoding ADAMTS-J1 in a biological sample containing nucleic acid material comprising:

- (a) hybridizing an isolated polynucleotide of the invention that is specific to ADAMTS-J1 to the nucleic acid material of the biological sample, thereby forming a hybridization complex; and
- (b) detecting the hybridization complex, wherein presence of the hybridization complex correlates with the presence of the polynucleotide encoding ADAMTS-J1 in the biological sample.

[0021] In a further embodiment, the invention relates to a method for identifying a substrate for ADAMTS-J1 comprising contacting a polypeptide comprising an enzymatically active polypeptide of the invention with a candidate substrate and determining either conversion of substrate to product or binding of the polypeptide to the substrate.

[0022] The invention also relates to a method for treating arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock comprising administering a therapeutically effective amount of an agonist or antagonist, of ADAMTS-J1 in combination with a pharmaceutically acceptable carrier.

[0023] The invention also relates to a method for treating arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock comprising administering a polypeptide of the invention in combination with a pharmaceutically acceptable carrier.

[0024] The invention also relates to a method for treating arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head

trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression; peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock comprising administering a polynucleotide of the invention in combination with a pharmaceutically acceptable carrier.

[0025] The invention further relates to a pharmaceutical composition for the treatment of arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock comprising a therapeutically effective amount of an agonist or antagonist, of ADAMTS-J1 in combination with a pharmaceutically acceptable carrier.

[0026] The invention also relates to a pharmaceutical composition for the treatment of arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock comprising a polypeptide of the invention in combination with a pharmaceutically acceptable carrier.

[0027] The invention also relates to a pharmaceutical composition for the treatment of arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock comprising a polynucleotide of the invention in combination with a pharmaceutically acceptable carrier.

Brief Description Of The Drawings

[0028] FIGS. 1, 2, 3, and 4 show polynucleotide coding sequences of alternative splice forms of ADAMTS-J1 [SEQ ID NOS: 1, 2, 3, and 4].

[0029] FIG. 5, 6, 7, and 8 show polypeptide sequences corresponding to ADAMTS-J1 splice forms [SEQ ID NOS: 5, 6, 7, and 8].

[0030] FIG. 9 shows the partial cDNA sequence of ADAMTS-J1 identified by library screening including 3' untranslated and poly-adenylation sequences [SEQ ID NO: 9]

[0031] FIGS. 10A and B show a detailed description of the domains of ADAMTS-J1.1.

[0032] FIG. 11 shows the genomic structure of ADAMTS-J1, patterns of splicing that give rise to the four alternative forms and the corresponding domains of the ADAMTS family of proteins.

[0033] FIG. 12 shows homology of the ADAMTS-J1 polypeptide metalloprotease domain with those of other ADAMTS proteins.

[0034] FIG. 13 shows a Western Blot analysis of secreted and cell associated ADAMTS-J1-FLAG fusion proteins after transformation of HEK 293 cells with recombinant expression constructs.

Detailed Description Of The Invention

[0035] We have found relatively high levels of polynucleotide encoding ADAMTS-J1 proteins in cDNA prepared from osteoarthritic cartilage as well as in cDNA from human brain, heart, lung and liver.

Definitions

[0036] The following definitions are provided to facilitate understanding of terms used herein.

[0037] "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of a Fab or other immunoglobulin expression library.

[0038] "Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example tritylated bases and unusual bases such as inosine. A variety of modifications have been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

[0039] "Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. "Polypeptides" may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslational natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, *Proteins - structure and molecular properties*, 2nd Ed., T.E. Creighton, W.H. Freeman and Company, New York, 1993; F. Wold, *Posttranslational protein modifications: perspectives and prospects*, pgs. 1-12 in *Posttranslational covalent modification of proteins*, B.C. Johnson, Ed., Academic Press, New York, 1983; S. Seifter and S. Englard, *Analysis for protein modifications and nonprotein cofactors*, 182 *Methods of Enzymology* 626 (1990); S.I. Rattan et al., *Protein synthesis, posttranslational modifications, and aging*, 663 *Ann NY Acad Sci* 48 (1992).

[0040] "Variant" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions and/or deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or a polypeptide may be naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis tech-

niques or by direct synthesis.

[0041] "Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" per se has an art-recognized meaning and can be calculated using published techniques. See, for example, *Computational molecular biology*, A.M. Lesk, ed., Oxford University Press, New York, 1988; *Biocomputing: informatics and genome projects*, D.W. Smith, ed., Academic Press, New York, 1993; *Computer analysis of sequence data, part 1*, A.M. Griffin, and H.G. Griffin, eds., Humana Press, New Jersey, 1994; *Sequence analysis in molecular biology*, G. von Heinje, ed., Academic Press, 1987; and *Sequence analysis primer*, M. Gribskov and J. Devereux, eds., M Stockton Press, New York, 1991. While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package; J. Devereux, et al., *A comprehensive set of sequence analysis programs for the VAX*, 12(1) Nucleic Acids Research 387 (January 1984); BLASTP; BLASTN; FASTA; S.F. Altschul et al., *Basic local alignment search tool*, 215(3) Journal of Molecular Biology 403 (October 1990). Among the methods stated above to determine identity, the preferred method is BLASTP.

[0042] As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of FIG. 1, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of FIG. 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

[0043] Similarly, by a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence of FIG. 2, it is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of FIG. 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

ADAMTS-J1 Polypeptides

[0044] In one aspect, the present invention relates to ADAMTS-J1 polypeptides. The ADAMTS-J1 polypeptides include the polypeptides of FIG. 5-8, as well as polypeptides comprising an amino acid sequence of FIG. 5-8, and polypeptides comprising an amino acid sequence that has at least 80% identity to that of FIG. 5-8, preferably at least 90% identity, more preferably at least 95% identity to FIG. 5-8, and most preferably at least 97-99% identity to FIG. 5-8.

[0045] The ADAMTS-J1 polypeptides may be in the form of an unprocessed or partially processed precursor, or the "mature" protein, which may in turn be a part of a larger protein such as a fusion protein. The mature form should normally begin with or near amino acid 224 (beginning with NAIR...) and continue to the carboxyl terminus. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequence, sequences which aid in purification or identification such as multiple histidine residues, a FLAG Tag, or an additional sequence for stability during recombinant production.

[0046] Fragments of the ADAMTS-J1 polypeptides are also included in the invention. A fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of the amino acid sequence of the aforementioned ADAMTS-J1 polypeptides. As with ADAMTS-J1 polypeptides, fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region.

[0047] Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of ADAMTS-J1 polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus. Also preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions,

hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Also preferred are biologically active fragments. Biologically active fragments are those that mediate one or more ADAMTS-J1 activities, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Most preferred are fragments that comprise one or more of the domains shown in Fig. 10. In particularly preferred embodiments, the fragment comprises the metalloproteinase domain, the disintegrin domain or the thrombospondin domain. In another embodiment, the polypeptide comprises amino acids 390-413 of SEQ ID NO: 5, which encompasses an extension of the zinc binding motif.

[0048] Such fragments are conventionally employed by themselves, or as part of fusion proteins. For example, expression vectors can be constructed that will express a fusion protein comprising a protein or polypeptide of the present invention. For example, as described in the Examples below, the three splice forms of ADAMTS-J1 (1.1, 1.2 and 1.3) were cloned into a mammalian expression construct (a derivative of pCDNA3.1, Invitrogen Corporation) with the addition of a FLAG epitope tag fused to the C terminus (FIG. 13). Such fusion proteins can be used, e.g., to raise antisera against the protein, to study the biochemical properties of the protein, to engineer a protein exhibiting different immunological or functional properties, to aid in the identification or purification, to improve the stability, of a recombinantly-expressed protein, or as therapeutic agents. Possible fusion protein expression vectors include but are not limited to vectors incorporating sequences that encode β -galactosidase and trpE fusions, maltose-binding protein fusions (pMal series; New England Biolabs), glutathione-S-transferase fusions (pGEX series; Pharmacia), polyhistidine fusions (pET series; Novagen Inc., Madison, WI), and thioredoxin fusions (pTrxFus; Invitrogen, Carlsbad, CA). As one example, the disintegrin domain or TSP domain, or a polypeptide comprising a variant or fragment thereof, may be administered alone, or as part of a fusion protein, to competitively inhibit in vivo or in vitro interactions with the native disintegrin domain or TSP domain. Methods are well-known in the art for constructing expression vectors encoding these and other fusion proteins.

[0049] Variants of the defined sequence and fragments also form part of the present invention. Preferred variants are those that vary from the referents by conservative amino acid substitutions, i.e., those that substitute a residue with another of like characteristics. Typical conservative substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; and among the aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5 to 10, 1 to 5, or 1 to 2 amino acids are substituted, deleted, or added in any combination.

[0050] The ADAMTS-J1 polypeptides of the invention can be prepared in any suitable manner. The polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, and polypeptides produced by a combination of these methods. These methods are well understood in the art.

[0051] Another embodiment of the present invention is an isolated ADAMTS-J1 polypeptide. An isolated polypeptide is one that has been substantially removed from its natural milieu. As isolated ADAMTS-J1 polypeptide can, for example, be obtained from its natural source, be produced using recombinant technology, or be synthesized chemically. An isolated ADAMTS-J1 polypeptide can be full-length ADAMTS-J1 polypeptide, the predicted mature form processed by furin cleavage of the prodomain (amino acid 104 with the predicted mature form beginning NAIR...), or any homologue of such a polypeptide, such as an ADAMTS-J1 polypeptide in which amino acids have been deleted, inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitoylation, amidation and/or addition of glycosylphosphatidyl inositol). A homologue of an ADAMTS-J1 polypeptide is a polypeptide having an amino acid sequence that is sufficiently similar to a natural ADAMTS-J1 polypeptide amino acid sequence that a nucleic acid sequence encoding the homologue is capable of hybridizing under stringent conditions to a nucleic acid sequence encoding the natural ADAMTS-J1 polypeptide amino acid sequence disclosed herein. As used herein, "stringent hybridization conditions" refers to hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (see Ausubel *et al.* (eds.), 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3). A homologue of ADAMTS-J1 polypeptide also includes a polypeptide having an amino acid sequence that is sufficiently cross-reactive such that the homologue has the ability to elicit an immune response against at least one epitope of naturally-occurring ADAMTS-J1 polypeptide. Preferably the homologue retains one or more biological activities of ADAMTS-J1.

[0052] The minimal length of a protein homologue of the present invention is sufficient to be encoded by a nucleic acid molecule capable of forming a stable hybrid with the complementary sequence of a nucleic acid molecule encoding the corresponding natural protein. As such, the size of the nucleic acid molecule encoding such a protein homologue is dependent on nucleic acid composition, percent homology between the nucleic acid molecule and complementary sequence, as well as upon hybridization conditions per se (e.g., temperature, salt concentration and formamide concentration). The minimal size of such nucleic acid is typically at least about 12 to about 15 nucleotides in length if the nucleic acid molecules are GC-rich and at least about 15 to about 17 bases in length if they are AT-rich. The minimal size of a nucleic acid molecule used to encode an ADAMTS-J1 protein homologue of the present invention is from

about 20 to about 25 nucleotides in length. There is no limit, other than a practical limit, on the maximal size of such a nucleic acid molecule in that the nucleic acid molecule can include a portion of a gene, an entire gene, or multiple genes, or portions thereof. In one embodiment, the minimal size of an ADAMTS-J1 protein homologue of the present invention is from 10, more preferably 12, even more preferably 25, amino acids in length. In another embodiment, a polypeptide of the invention comprises an amino acid sequence of more than about 10, or 25, preferably more than 75, more preferably more than 100, amino acids that is identical to an amino acid sequence of SEQ ID NO: 2. Preferred protein or polypeptide sizes depend on whether a full-length, multivalent protein (i.e., fusion protein having more than one domain each of which has a function), or a functional portion of such a protein is desired. Functional portions are obtainable based on the domains described herein, knowledge in the art concerning such domains and known assays for such domain, or its functional activity. Useful protein fragments or other polypeptides can also be screened for based on antigenic cross-reactivity with the ADAMTS-J1 protein of SEQ ID NO: 5-8.

[0053] ADAMTS-J1 protein homologues of the invention include allelic variations of the natural gene encoding the ADAMTS-J1 protein. A "natural" gene is that found most often in nature. ADAMTS-J1 protein homologues can be produced using techniques known in the art, including, but not limited to, direct modifications to a gene encoding a protein using, for example, classic or recombinant DNA techniques to effect random or targeted mutagenesis.

[0054] In another embodiment, an ADAMTS-J1 polypeptide of the present invention comprises a portion of the ADAMTS-J1 polypeptide disclosed herein, this portion having a molecular weight of about 25 kD (determined by Tris-glycine SDS-PAGE and resolved using methods standard in the art).

[0055] In yet another embodiment, an ADAMTS-J1 polypeptide of the present invention comprises at least a portion of an ADAMTS-J1 polypeptide encoded by a mRNA (messenger ribonucleic acid), having a length of about 681 nucleotides.

[0056] The present invention, encompasses the ADAMTS-J1 proteins that have undergone posttranslational modification. Such modification can include, for example, glycosylation (e.g., including addition of N-linked and/or O-linked oligosaccharides) or posttranslational conformational changes or posttranslational deletions.

[0057] Based on the 29-36% identity in the metalloprotease domain of ADAMTS-J1 as compared to other ADAMTS family members, ADAMTS-J1 may have one or more proteolytic activities (e.g. collagenase, aggrecanase, procollagen protease) as well as anti-angiogenic activities that may or may not require the presence of the thrombospondin domains. See, FIGS. 10 and 11. These possible activities of ADAMTS-J1 can be tested using techniques known to those skilled in the art. See, e.g., P.D. Brown et al., *Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines*, 50(19) Cancer Research 6184 (October 1990); F. Vazquez et al., *METH-1 a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angi inhibitory activity*, 274 The Journal of Biological Chemistry 23349 (Aug. 1999); E.C. Arner et al., *Generation and characterization of aggrecanase*, 274 The Journal of Biological Chemistry 6594 (Mar. 1999); A. Colige et al., *cDNA cloning and expression of bovine procollagen I N-proteinase: A new member of the superfamily of zinc-metalloproteinases with binding sites for cell and other matrix components* 94 Proceedings of the National Academy of Sciences (USA) 2374 (March 1997).

ADAMTS-J1 Polynucleotides

[0058] Another aspect of the invention relates to ADAMTS-J1 polynucleotides. ADAMTS-J1 polynucleotides include isolated polynucleotides which encode the ADAMTS-J1 polypeptides and fragments, and polynucleotides closely related thereto. This includes the naturally occurring splice variants identified by cloning (FIGS. 1-3) and that predicted by database searching (FIG. 4). More specifically, ADAMTS-J1 polynucleotides of the invention include a polynucleotide comprising the nucleotide sequence set forth in FIGS. 1-4 encoding a ADAMTS-J1 polypeptide of FIGS. 5-8, respectively, and a polynucleotide having the particular sequence of FIGS. 1-4. ADAMTS-J1 polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the ADAMTS-J1 polypeptide of FIGS. 5-8, and a polynucleotide that is at least 80% identical to the polynucleotide sequence of FIGS. 1-4. In this regard, polynucleotides at least 90% identical are particularly preferred, and those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred.

[0059] In one embodiment, the nucleic acid molecule of the invention has a nucleotide sequence has between 1 and 50, more preferably between 1 and 25, and most preferably between 1 and 5 nucleotides inserted, deleted, or substituted with respect to the sequence of SEQ ID NOS: 1-4.

[0060] ADAMTS-J1 polynucleotides of the invention also encompass nucleotide sequences which have sufficient identity to the nucleotide sequence contained in FIGS. 1-4 to hybridize under conditions useable for amplification or for use as a probe or marker for ADAMTS-J1. Such sequences are typically 15 to 25 nucleotides in length with a target of 50% GC content and useful in PCR amplification or oligonucleotide hybridization methods well known to those skilled in the art. (See, e.g., Promega Protocols and Applications Guide, Third Edition, (1996), ISBN 1-8822474-57-1).

[0061] In one embodiment, the isolated nucleic acid molecule comprises a fragment of SEQ ID NOS: 1-4 that is specific for ADAMTS-J1, i.e., specifically acts as a probe for SEQ ID NOS: 1-4. The fragment may be at least, e.g., 15, 25, 35, 45 or 75 nucleotides in length.

[0062] Another embodiment of the present invention is an isolated nucleic acid molecule capable of hybridizing, under stringent conditions, with ADAMTS-J1 polypeptide gene (FIGS. 1-4) encoding one or more of the ADAMTS-J1 polypeptides of the present invention.

[0063] An isolated nucleic acid of the invention can include DNA, RNA or derivatives of either DNA or RNA.

[0064] An isolated nucleic acid molecule of the present invention can be obtained from its natural source either as an entire (i.e., complete) gene or a portion thereof capable of forming a stable hybrid with that gene. As used herein, the phrase "at least a portion of" an entity refers to an amount of the entity that is at least sufficient to have functional aspects of that entity. For example, at least a portion of a nucleic acid sequence, as used herein, is an amount of a nucleic acid sequence capable of forming a stable hybrid with a particular desired gene (e.g., ADAMTS genes) under stringent hybridization conditions. An isolated nucleic acid molecule of the present invention can also be produced using recombinant technology (e.g., polymerase chain reaction (PCR) amplification, cloning) or chemical synthesis. Isolated ADAMTS-J1 protein nucleic acid molecules include natural nucleic acid molecules and homologues thereof, including, but not limited to natural allelic variants and modified nucleic acid molecules in which nucleotides have been inserted, deleted, substituted, and/or inverted in a manner that does not substantially interfere with the nucleic acid molecule's ability to encode an ADAMTS-J1 protein of the present invention or to form stable hybrids under stringent conditions with natural nucleic acid molecule isolates encoding an ADAMTS-J1 protein.

[0065] The invention also provides polynucleotides that are complementary to ADAMTS-J1 polynucleotides described above.

Expression of ADAMTS-J1

[0066] In one embodiment, an isolated ADAMTS-J1 protein of the present invention is produced by culturing a recombinant cell capable of expressing the protein under conditions effective to produce the protein, and recovering the protein. Preferred cells include bacterial (e.g., *E. coli*), yeast (e.g., *Pichia*), insect (e.g., SF9) or mammalian cells (e.g., CHO, Cos 7, and HEK 293). The recombinant cell is capable of expressing the ADAMTS-J1 protein and is produced by transforming a host cell with one or more nucleic acid molecules of the present invention. Such recombinant cells are part of the present invention. Suitable transformation techniques include, but are not limited to, transfection, electroporation, microinjection, lipofection, adsorption and protoplast fusion. Recombinant cells of the invention may remain unicellular or may grow into a tissue organ or a multicellular organism. Nucleic acid molecules of the present invention used to transform cells according to conventional techniques can remain extrachromosomal or can integrate into one or more sites within a chromosome of the transformed (i.e., recombinant) cell in such a manner that their ability to be expressed is retained.

[0067] Suitable host cells for transforming a cell include any cell capable of producing ADAMTS-J1 proteins of the present invention after being transformed with at least one nucleic acid molecule of the present invention. Host cells can be either untransformed cells or cells that are already transformed with at least one nucleic acid molecule of the present invention. Suitable host cells include bacterial, fungal (including yeast), insect, animal and plant cells.

[0068] The present invention also encompasses a recombinant vector which comprises a polynucleotide of the present invention inserted into a vector capable of delivering the polynucleotide into a host cell. Such a vector normally contains heterologous nucleic acid sequences, for example nucleic acid sequences that are not naturally found adjacent to ADAMTS-J1 protein nucleic acid molecules of the present invention. The vector can be either DNA or RNA, and either prokaryotic or eukaryotic, and is typically a virus or a plasmid. Recombinant vectors can be used in cloning, sequencing, and/or otherwise manipulating or expressing ADAMTS-J1 polynucleotides of the present invention.

[0069] In one embodiment of the invention, a recombinant cell is produced by transforming a host cell with one or more recombinant molecules, each comprising one or more polynucleotide molecules of the present invention operatively linked to an expression vector containing one or more transcription control sequences. The phrase "operatively linked" refers to a nucleic acid molecule inserted into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell. As used herein, the phrase "expression vector" refers to a DNA or RNA vector that is capable of transforming a host cell and of effecting expression of a specified nucleic acid molecule.

[0070] Preferably, the expression vector is also capable of replicating within the host cell. Expression vectors can be either prokaryotic or eukaryotic, and are typically viruses or plasmids. Expression vectors of the present invention include vectors that effect direct gene expression in bacterial, fungal, insect, animal, and/or plant cells. Nucleic acid molecules of the present invention can be operatively linked to expression vectors containing regulatory sequences such as promoters, operators, repressors, enhancers, termination sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell and that control the expression of nucleic acid molecules. Transcription control sequences that can be used in the present invention include those capable of controlling the

initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcriptional initiation, such as promoter, enhancer, operator and repressor sequences. Suitable transcription control sequences include those that function in one of the recombinant cells of the present invention. A variety of such transcription control sequences are known to those skilled in the art. Preferred transcription control sequences include those which function in bacterial yeast and mammalian cells, such as, but not limited to, tac, lac, trp, trc, oxy-pro, omp/lpp, rmB, bacteriophage lambda (λ) (such as λ_P and λ_{P_R} and fusions that include such promoters), bacteriophage T7, T7lac, bacteriophage T3, bacteriophage SP6, bacteriophage SPO1, metallothionein, alpha mating factor, baculovirus, vaccinia virus, herpesvirus, poxvirus, adenovirus, simian virus 40, retrovirus action, retroviral long terminal repeat, Rous sarcoma virus, heat shock, phosphate and nitrate transcription control sequences, as well as other sequences capable of controlling gene expression in prokaryotic or eukaryotic cells. Additional suitable transcription control sequences include tissue-specific promoters and enhancers as well as lymphokine-inducible promoters (e.g., promoters inducible by interferons or interleukins). Transcription control sequences useful in practicing the present invention include naturally occurring sequences associated with DNA encoding an ADAMTS-J1 protein.

[0071] Preferred nucleic acid molecules for insertion into an expression vector include nucleic acid molecules encoding at least a portion of an ADAMTS-J1 protein, or a homologue thereof. Expression vectors of the present invention may also contain fusion sequences, e.g., as discussed above, which allow expression of nucleic acid molecules of the present invention as fusion proteins. Inclusion of a fusion sequence in an ADAMTS-J1 nucleic acid molecule of the present invention can enhance stability during production, storage, or use of the protein encoded by the nucleic acid molecule. Furthermore, a fusion segment can simplify detection and purification of an ADAMTS-J1 protein, enabling purification by affinity chromatography. Fusion segments can be of any size that affords the desired function (e.g., increased stability and/or easier purification). It is within the scope of the present invention to use one or more fusion segments. Fusion segments can be joined to amino and/or carboxyl termini of the ADAMTS-J1 protein or polypeptide of the present invention. Linkages between fusion segments and ADAMTS-J1 proteins can be constructed to be susceptible to cleavage to enable straightforward recovery of the ADAMTS-J1 proteins. Fusion proteins are preferably produced by culturing a recombinant cell transformed with nucleic acid sequences that encode the fusion segment attached to either the carboxyl and/or amino terminal end of a ADAMTS-J1 polypeptide of the invention.

[0072] The present invention includes recombinant cells resulting from transformation with a nucleic acid molecule of the present invention. Preferred recombinant cells are transformed with a nucleic acid molecule that encodes at least a portion of an ADAMTS-J1 protein, or a homologue thereof. Amplifying the copy number of nucleic acid sequences of the invention can be accomplished by increasing the copy number of the nucleic acid sequence in the cell's genome or by introducing additional copies of the nucleic acid sequence by transformation. Copy number amplification is conducted in a manner such that greater amounts of enzyme are produced, leading to enhanced conversion of substrate to product. Transformation can be accomplished using any process by which nucleic acids are transformed into cells to enhance enzyme synthesis. Prior to transformation, the nucleic acid sequence can, if desired, be manipulated to encode an enzyme having a higher specific activity.

[0073] In accordance with the present invention, recombinant cells are used to produce an ADAMTS-J1 protein of the present invention by culturing such cells under conditions effective to produce such a protein, and the protein recovered. Effective conditions include, but are not limited to, appropriate media, bioreactor, temperature, pH and oxygen conditions that permit protein production. Suitable media are typically aqueous and comprise assimilable carbohydrate, nitrogen and phosphate sources, as well as appropriate salts, minerals, metals and other nutrients, such as vitamins. The medium may comprise complex nutrients, or may be minimal.

[0074] Cells of the present invention can be cultured in conventional fermentation bioreactors, which include, but are not limited to, batch, fed-batch, cell recycle, and continuous fermentors. Culturing can also be conducted in shake flasks, test tubes, microtiter dishes, and petri plates. Culturing is carried out at a temperature, pH and oxygen content appropriate for the recombinant cell. Such culturing is within the expertise of one of ordinary skill in this art.

[0075] Depending on the vector and host system used for production, resultant ADAMTS-J1 proteins may either remain within the recombinant cell or be secreted into the fermentation medium. "Recovering the protein" according to the invention may involve simply collecting the fermentation medium or cells containing the protein and need not include additional steps of separation or purification. ADAMTS-J1 proteins of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, chromatofocusing and differential solubilization.

[0076] In addition, an ADAMTS-J1 protein of the present invention can be produced by isolating the ADAMTS-J1 protein from cells expressing the ADAMTS-J1 protein recovered from transgenic animal, or from fluid, such as milk, recovered from such an animal. An isolated protein or polypeptide of the present invention can be used to formulate a therapeutic composition as discussed further below.

Antibodies to ADAMTS-J1

[0077] The present invention also includes antibodies capable of selectively binding to an ADAMTS-J1 protein or polypeptide of the present invention. Polyclonal populations of anti-ADAMTS-J1 antibodies can be contained in an ADAMTS-J1 antiserum. Binding can be measured using a variety of methods known to those skilled in the art including immunoblot assays, immunoprecipitation assays, enzyme immunoassays (e.g., ELISA), radioimmunoassay, immunofluorescent antibody assays and immunoelectron microscopy; see, for example, Sambrook et al., *Molecular cloning: a laboratory manual*, Cold Spring Harbor Labs Press, 1989.

[0078] Antibodies of the present invention can be either monoclonal or polyclonal antibodies and can be prepared using techniques standard in the art. Antibodies of the present invention include functional equivalents such as antibody fragments and genetically-engineered antibodies, including single chain antibodies that are capable of selectively binding to at least one of the epitopes of the protein used to obtain antibodies. Preferably, antibodies are raised in response to proteins that are encoded, at least in part, by an ADAMTS-J1 nucleic acid molecule.

Identification of ADAMTS-J1 substrates

[0079] The present invention also encompasses methods for identifying ADAMTS-J1 substrates. Such methods include those wherein a candidate substrate is contacted with a polypeptide comprising an enzymatically active ADAMTS-J1 polypeptide of the invention, and conversion of substrate to product is determined, or binding of polypeptide to the candidate substrate determined. The invention also encompasses rational drug design conducted using computer software that calculates interactions between candidate compounds and polypeptides or polynucleotides of the invention.

[0080] Substrates may be identified by a candidate protein or synthetic substrate approach. For example, candidate proteins can be cast within an agarose gel matrix and the ability of the ADAMTS-J1 protein to digest the protein determined using protein zymography. See, P.D. Brown et al., *Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines*, 50(19) Cancer Research 6184 (October 1990). Alternatively, a phage display or fluorometric peptide library can be screened to identify substrates of the protein. See, D.R. O'Boyle et al., *Identification of a novel peptide substrate of HSV-1 protease using substrate phage display*, 236(2) Virology 338 (September 1997).

Agonists/antagonists of ADAMTS-J1

[0081] The present invention also includes assays for determining agonists and/or antagonists of ADAMTS-J1. Assays for determining aggrecanase, collagenase, procollagen protease and/or angiogenic activities may be used to identify agonist or antagonist compounds, preferably small molecular weight compounds of less than 700 daltons. The compounds may contain a hydroxamic acid moiety or an optionally substituted heterocyclic nucleus, or an aryl or heteroaryl sulfonamide moiety, which compounds inhibit or stimulate the activity of endogenous or recombinant ADAMTS-J1. E.C. Arner et al., *Generation and characterization of aggrecanase. A soluble, cartilage-derived aggrecan-degrading activity*, 274 Journal of Biological Chemistry 6594 (March 1999); M.D. Tortorella et al., *supra*; A. Colige et al., *supra*; K. Kuno et al., *supra*. ELISA or fluorescent substrate assays can be performed to determine agonists or antagonists, or to determine specific proteolytic activity, of an ADAMTS-J1 protein.

Diagnostic Assays

[0082] The present invention also includes processes for diagnosing diseases or susceptibility to diseases related to expression and/or activity of ADAMTS-J1. Such diseases may be identified by determining the presence or absence of a mutation in the nucleotide sequence encoding said ADAMTS-J1 polypeptide in the genome of a patient. Alternately, the presence or amount of ADAMTS-J1 polypeptide in a sample derived from a patient may be determined as an indicator of disease or susceptibility to disease. Such diagnosis may be performed for diseases including the following: arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis,

multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, diabetic shock, infertility and other diseases characterized by metalloproteinase activity and/or characterized by mammalian adamalysin activity.

Therapeutic compositions and uses of ADAMTS-J1

[0083] In one embodiment of the present invention, an antibody, agonist, antagonist, substrate and/or variant of ADAMTS-J1, or a polypeptide or polynucleotide of the invention, is employed in a therapeutic composition for treatment of arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, diabetic shock, infertility or other diseases characterized by metalloproteinase activity and/or mammalian adamalysin activity.

[0084] In one embodiment, polynucleotides of the invention can, for example, be employed to transform cells in gene therapy application, e.g., as part of in vivo or ex vivo gene therapy. Polynucleotides can also be employed in antisense therapy, and in the construction of ribozymes. Use of polynucleotides in these methods is known to those skilled in this art.

[0085] For administration to mammals, including humans, a variety of conventional routes may be used including oral, parenteral (e.g., intravenous, intramuscular or subcutaneous), buccal, anal and topical.

[0086] For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. In the case of animals, they are advantageously contained in an animal feed or drinking water in a concentration of 5-5000 ppm, preferably 25 to 500 ppm.

[0087] For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared. Solutions of the therapeutic compound in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to 50 mg/kg/day, advantageously 0.2 to 10 mg/kg/day given in a single dose or up to 3 divided doses.

[0088] Active compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

[0089] For intranasal administration or administration by inhalation, active compounds are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

[0090] A therapeutic composition of the present invention can be administered to any subject having a medical disorder as herein described. Acceptable protocols by which to administer therapeutic compounds of the present invention in an effective manner vary according to individual dose size, number of doses, frequency of dose administration and

mode of administration. Determination of appropriate protocols is accomplished by those skilled in the art without undue experimentation. An effective dose refers to a dose capable of treating a subject for a medical disorder as described herein. Effective doses vary depending upon, for example, the therapeutic composition used, the medical disorder being treated and the size and type of recipient animal.

[0091] The dosage and length of treatment depends on the disease state being treated. The duration of treatment may be a day, a week or longer and may last over the lifetime of the patient.

Identification of ADAMTS-J1

[0092] For identification of novel ADAMTS gene family members, a non-redundant set of publicly available protein sequences was assembled (accession numbers: D67076, AJ003125, AB002364, AB014588). A series of low stringency BLAST searches were then performed against the LifeSeq Gold™ database (Incyte) using each of the above protein sequences as queries. A 278bp EST was identified containing a Zn-binding motif and upstream sequence. This sequence was used to design PCR primers, and a panel of libraries was screened to determine a source for further cloning. An abundant product was obtained from an osteoarthritic cartilage cDNA library, which was then screened by RecA-mediated homology capture. Colonies hybridizing to the capture sequence were isolated, and miniprep DNA was used for PCR with outer primers. Two positive clones were identified, one of which was sequenced in its entirety (FIG. 9). BLASTP 2.0.9 analysis showed high homology to a number of ADAMTS family members, as indicated in the alignment in Figure 12.

[0093] In order to identify the 5' end of the gene, the HTG (high throughput genomic) section of Genbank was searched with the sequence obtained. A match to the start of this sequence was found in a 32kb contig in the entry AC015723. To identify the 5' prime exons two gene prediction tools (Genscan and Genie) were used on the genomic contig. Exons which showed some homology to known ADAMTSs and were of appropriate size and position were predicted to be the start of the coding region.

[0094] The 3' end of the sequence was found to match to the HTG entry AC022710. By comparing the genomic sequence to known ADAMTSs three exons with homology to the 3' end of ADAMTSs were predicted beyond the final exon of the ADAMTS-J1 sequence. This potential extended splice variant was confirmed by identification of a cDNA, the Incyte EST 4739224F7, which covers the 3' end of the ADAMTS-J1 sequence except for an alternate splice site at the final exon and continues into the 3 extra predicted exons.

[0095] In order to generate the 5' cDNA predicted by analysis of the genomic sequence, but missing from the library clone [FIG. 9] an RT-PCR strategy was utilized. RNA from human OA chondrocytes as well as from adult and fetal brain (CloneTech Inc., Palo Alto, CA) were used as templates. First strand cDNA was primed with anti-sense primers to the 3' end [primer J05: tca ctt gtc atc gtc gtc ctt gta gtc ACC CAG AAA GCT GTG GGC A; (SEQ ID NO: 10) lower case nucleotides correspond to the addition of a FLAG tag] or from the middle [primer J01: GGA CGT TGT CGT AGC AGG AC] (SEQ ID NO: 11) of the gene. The 5' PCR primer [J02: gga att CGG GTA CCA TGT GTG ACG GC (SEQ ID NO: 12); lower case nucleotides add an EcoRI restriction site]. Products from RT-PCR reactions were cloned and nucleotide sequence determined. The missing 5' end from the genomic clone was found to be expressed in fetal brain [see FIG. 1, SEQ ID NO: 1, showing the nucleic acid sequence of ADAMTS-J1.1], while an alternative 5' splice was identified in both OA chondrocytes and fetal brain RNA [see FIG. 3, SEQ ID NO: 3, showing the nucleic acid sequence of ADAMTS-J1.2]. The alternative 3' splice was found to be expressed in fetal brain [see FIG. 2, SEQ ID NO: 2, showing the nucleic acid sequence of ADAMTS-J1.3]. FIG. 4, SEQ ID NO: 4 shows the nucleic acid sequence of an alternative splice variant, ADAMTS-J1.4, that was identified. Corresponding amino acid sequences for the splice variants are shown in FIGS. 5-8. A qualitative PCR analysis was consistent with the expression of ADAMTS-J1 forms in human OA chondrocytes, adult and fetal brain, heart, liver and kidney.

[0096] FIGS. 10A and B show a detailed description of the domains of ADAMTS-J1.1. The sequences of the domains of ADAMTS-J1.2, 1.2, 1.3, and 1.4 can be easily found by identifying the corresponding regions of 1.1.

[0097] FIG. 11 shows the genomic structure of ADAMTS-J1, patterns of splicing that give rise to the four alternative forms and the corresponding domains of the ADAMTS family of proteins. In this figure, "PRO" indicates prodomain, "TSP" indicates the thrombospondin domain, "SS" indicates signal sequence, and "no genomic" indicates that no genomic sequence was found for the sequence spanning the indicated region.

Expression of ADAMTS-J1 Forms

[0098] Mammalian expression constructs corresponding to the three splice forms of ADAMTS-J1 and containing a FLAG-epitope tag were prepared by cloning the PCR products into a pCDNA3.1-based vector (Invitrogen, Carlsbad, CA). Sequence verified plasmids were transfected into HEK 293 cells (ATCC) using a cationic lipid, LF2000 (Life Technologies Inc., Gaithersburg, MD). Eight hours post transfection cells were changed into IS293 media (Irvine Scientific, Irvine, CA). After 48 hours media was collected and cellular proteins harvested in 2X Tris-Glycine Sample buffer

(Novex). Media was concentrated by acid precipitation (10% final TCA).

[0099] Expression of the secreted (1×10^6 cell equivalents) and cell-associated (1×10^5 cells) proteins were analyzed by Western blot. In particular, samples and prestained/biotinylated molecular weight markers were resolved by SDS-PAGE (4-20% tris-glycine, Novex), and transferred to nitrocellulose membrane. FLAG-reactive proteins were identified by incubating the Western blots with an HRP-conjugated anti-FLAG antibody (M2, Sigma Inc., St. Louis, MO) and visualized by chemiluminescence (Super Signal, Pierce Inc.) and imaging on a Lumilimager (Roche Diagnostics, Indianapolis, IN).

[0100] Consistent with the predicted secreted (80 kD) and furin processed (58 kD) forms of 1.1, FLAG reactive products were detected in the media of transfected cells as indicated in FIG. 13 by the (<). Likewise, consistent with the predicted secreted (67 kD) and furin processed (45 kD) forms of 1.2, FLAG reactive products were detected in the media (*). No FLAG reactivity was detected in mock transfected cells (Un), those transfected with a construct expressing 1.3 or a form of 1.2* with multiple point mutations. FLAG reactive products specific to cells transfected with each splice form were identified in the analysis of cellular proteins, including the splice form 1.3 (■).

[0101] These results demonstrate that splice forms 1.1 and 1.2 give rise to secreted products of the expected molecular weight for secreted and furin processed polypeptides (FIG. 13). In addition, and consistent with observations in baculovirus expression systems, a construct expressing a form lacking most of the prodomain (splice form 1.3 and data not shown) fails to demonstrate the presence of a secreted product, but does show production of a cell associated product of approximately the correct size (FIG. 13). These results indicate that a prodomain is necessary for proper expression of secreted forms, and suggest function for the cell associated form, i.e., 1.3.

[0102] The foregoing description of the invention has been presented for purposes of illustration and description. Further, the description is not intended to limit the invention to the form disclosed herein. Consequently, variations and modifications commensurate with the above teachings, and the skill or knowledge in the relevant art are within the scope of the present invention. It is intended that the appended claims be construed to include alternate embodiments to the extent permitted by the prior art.

Sequence ID Listing

[0103] SEQ ID NOS: 1-4 are the nucleotide sequences of ADAMTS-J1 splice forms.

[0104] SEQ ID NOS: 5-8 are the deduced amino acid sequences of ADAMTS-J1 forms.

[0105] SEQ ID NO: 9 is the nucleotide sequence of the partial ADAMTS-J1 cDNA clone identified by library screening.

[0106] SEQ ID NOS: 10-12 are nucleotide sequences of PCR primers described herein.

SEQUENCE LISTING

5 <110> Pfizer Products Inc.
 <120> ADAMTS POLYPEPTIDES, NUCLEIC ACIDS ENCODING THEM, AND
 USES THEREOF
 <130> PC10736A
 10 <140>
 <141>
 <160> 12
 15 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 2235
 <212> DNA
 20 <213> Human
 <400> 1
 atgtgtgacg gcgcacctgct gcctccgctc gtcctgcccg tgctgtgtgt gctgggtttgg 60
 ggactggacc cgggcacagc tgtcggngac gcggcggccg acgtggaggt ggtgtctccg 120
 25 tggcgggtgc gccccgacga cgtgcacctg ccgcccgtgc ccgcagcccc cgggccccga 180
 cggcggcgac gccccgcac gccccagcc gccccgcgcg cccggcccgg agagcgcgc 240
 ctgtctgtgc acctgccggc cttcgggcgc gacctgtacc ttcagctgcg ccgcgacctg 300
 cgcttccctgt ccgcaggctt cgagggtgag gaggcgggcg cggcccggcg ccgcggccgc 360
 cccgcgcgagc tgtgtcttcta ctcgggccgt gtgtctcgcc accccggctc cctcgtctcg 420
 ctcagcgccct gcggcgccgc cggcgccctg gttggcctca ttcagcttgg gcaggagcag 480
 30 gtgctaatacc agccctcaa caactcccag ggccattca gtggacgaga acatctgatc 540
 aggcgcaaat ggtccttgac cccagacct tctgtgagg cccagagacc tgagcagctc 600
 tgcaagggtc taacagaaaa gaagaagccg acgtggggca ggccttcgcg ggactggcgg 660
 gagcggagga agcctatccg gtcaccagc gaggcacacg tggagacctt ggtggtggcc 720
 gacgcgcgaca tgggtgcagta ccacggggcc gaggccgccc agaggttcat cctgaccgtc 780
 atgaacatgg tatacaatat gtttcagcac cagagcctgg ggattaaaaa taacattcaa 840
 35 gtgaccaagc ttgtcctgct acgacaacgt cccgctaagt tgtccattgg gcaccatggt 900
 gagcgggtccc tggagagctt ctgtcactgg cagaacgagg agtatggagg agcgcgatac 960
 ctcggaataa accaggttcc cggcggaag gacgaccgc cctggtgga tctgtctgtg 1020
 tttgtgacca ggacagattt ctgtgtacac aaagatgaac cgtgtgacac tgttgaatt 1080
 gcttacttag gaggtgtgtg cagtgtctaa aggaagtgtg tgcttgccga agacaatggt 1140
 40 ctcaatttgg cctttaccat cggccatgag ctgggccaca acttgggcat gaaccaogac 1200
 gatgaccact catcttgccg tggcaggctc cacatcatgt caggagagtg ggtgaaaggc 1260
 cggaacccaa gtgacctctc ttggtcctcc tgcagccgag atgaccttga aaacttctc 1320
 aagtcaaaaag tcagcacctg cttgctagt caggacccca gaagccagca cacagtacgc 1380
 ctcccgacaca agctgcggg catgcactac agtccaacg agcagtgcc gatcctgttt 1440
 ggcatgaatg ccaccttctg cagaaacatg gagcatctaa tgtgtgtctg actgtggtgc 1500
 45 ctggtagaag gagacacatc ctgcaagacc aagctggacc ctcccctgga tggcacogag 1560
 tgtggggcag acaagtgggt ccgcgcgggg gagtgcgtga gcaagacgcc catcccgag 1620
 catgtggacg gagactggag cccgtggggc gcctggagca tgtgcagccg aacatgtggg 1680
 acgggagccc gcttcgggca gaggaaatgt gacaacccc cccctggggc tggaggoaca 1740
 cactgcccgg gtgccagtgt agaacatgcg gntgtcgaga acctgccctg cccaagggt 1800
 ctgcccagct tccgggacca gcagtgccag gcacacgacc ggctgagccc caagaagaaa 1860
 50 ggctgtctga cagccgtggt ggttgacgat aagccatgtg aactctactg ctcccccctc 1920
 gggaaggagt ccccaactgt ggtggccgac aggtccttg acggtacacc ctgcggggcc 1980
 tacgagactg atctctgcgt gcacggcaag tccagaaaaa tcggctgtga cggcatcacc 2040
 ggtctgtcag ccaaaagagg cagatgcggg gtctgcagcg gggacggcaa gacctgccac 2100
 ttggtgaagg gcgacttcag ccacgcccgg gggacaggtt atatogaagc tgccgtcatt 2160
 55 cctgtctggag ctgcgaggat ccgtgtggtg gaggataaac ctgcccacag ctttctgggt 2220
 aaaacacaaa tgact 2235

5 <210> 2
 <211> 1905
 <212> DNA
 <213> Human

10 <400> 2
 atgtgtgacg gcgcccctgct gcctccgctc gtccctgccc tgctgtctgct gctgggtttgg 60
 ggactggacc cgggcacagc tgtcggcgac gcggcgggcg acgtggaggt ggtgctccc 120
 tggcggtgac gccccgacga cgtgcacctg ccgcccgtgc ccgcagcccc cgggccccga 180
 cggcgggcgc gccccgcac gccccagcc gccccgcgcg cccggcccgg agagcgcgcc 240
 ctgctgctgc acctgocggc cttcggggcg gacctgtacc ttcagctgcg ccgcgacctg 300
 cgcttctctgt cccgaggcct cgagggtggag gagggcgggcg cggcccggcg ccgcggccgc 360
 15 cccgcgcagc tgtgcttcta ctcgggcccgt gtgctcggcc accccggctc cctcgtctcg 420
 ctcagcgccct gcggcgccgc cggcggcctg gttggcctca ttcagcttgg gcaggagcag 480
 gtgctaatac agccccctca caactcccag ggcccattca gtggacgaga acatctgac 540
 aggcgcaaat ggtccttgac ccccagccct tctgctgagg cccagagacc tgagcagctc 600
 tgcaagggttc taacagaaaa gaagaagccg acgtggggca ggccttcgcg ggactggcgg 660
 20 gagcgaggga acgctatccg gctcaccagc gagcacacgg tggagaccct ggtggtggcc 720
 gacgcccaga ttgtgcagta ccacggggcc gaggcgcgcc agaggttcat cctgaccgtc 780
 atgaacatgg tatacaatat gtttcagcac cagagcctgg ggattaaaaat taacattcaa 840
 gtgaccaagc ttgtcctgct acgacaacgt cccgctaagt tgtccattgg gcaccatggt 900
 gagcggtccc tggagagctt ctgtcactgg cagaacgagg agtatggagg ggcgcgatac 960
 ctcggcaata accaggttcc cggcggaag gacgacccgc ccttgggtga tgctgocgtg 1020
 25 tttgtgacca ggacagattt ctgtgtacac aaggatgaac cgtgtgacac tgttgggaatt 1080
 gcttacttag gaggtgtgtg cagtgtctag aggaagtgtg tgcttgccga agacaatggt 1140
 ctcaatttgg cctttaccat cgcccatgag ctggggccaca acttgggcat gaaccacgac 1200
 gatgaccact catcttgccg tggcaggctc cacatcatgt caggagagtg ggtgaaaggc 1260
 cggaacccaa gtgacctctc ttggtcctcc tgacgcccag atgaccttga aaacttcctc 1320
 30 aaccctgggc cctggaggcac aactgcccg ggtgccagtg tagaacatgc ggtctgcgag 1380
 aacctgccct gcccgaagg tctgcccagc ttccgggacc agcagtgccg ggcacacgac 1440
 cggctgagcc ccaagaagaa aggcctgctg acagccgtgg tggttgacga taagccatgt 1500
 gaactctact gctcgcccct cgggaaggag tcccaactgc tgggtggcga cagggtcctg 1560
 gacggtacac cctgcggggc ctacgagact gatctctgcg tgcacggcaa gtgccagaaa 1620
 atcggtctgt acggcatcat cgggtctgca gccaaagagg acagatgcgg ggtctgcagc 1680
 35 ggggacggca agacctgcc cttggtgaag ggcgacttca gccacgcccg ggggacagtt 1740
 aagaatgatc tctgtacgaa ggtatccaca tgtgtgatgg cagaggctgt tcccaagtgt 1800
 ttctcatggt atatcgaagc tgccgtcatt cctgctggag cctggtggtg 1860
 gaggataaac ctgcccacag ctttctgggt aaaacacaaa tgact 1905

40 <210> 3
 <211> 1698
 <212> DNA
 <213> Human

45 <400> 3
 atgtgtgacg gcgcccctgct gcctccgctc gtccctgccc tgctgtctgct gctgggtttgg 60
 ggactggacc cgggcacaga aaagaagaag ccgacgtggg gcaggccttc gcgggactgg 120
 cgggagcggg ggaacgctat ccggtccacc agcgagcaca cggtggagac cctggtggtg 180
 gccgacgcgc acatgggtgca gtaccacggg gccgaggccg cccagagggt catcctgacc 240
 50 gtcataaaca tggatataca tatgtttcag caccagagcc tggggattaa aattaacatt 300
 caagtgaaca agcttgtcct gctacgacaa cgtcccgtca agttgtccat tgggcacat 360
 ggtgagcggg ccttgagag cttctgtcac tggcagaaca aggagtatgg aggagcgcga 420
 tacctcggca ataaccagg tcccgccggg aaggacgacc cggccctggt ggtgctgct 480
 gtgtttgtga ccaggacaga tttctgtgta cacaaagatg aaccgtgtga cactgttggg 540
 attgcttact taggaggtgt gtgcagtgt aagaggaagt gtgtgcttgc cgaagacaat 600
 55 ggtctcaatt tggcctttac catcgcccat gagctgggac acaacttggg catgaaccac 660
 gacgatgacc actcatcttg cgctggcagg tcccacatca tgtcaggaga gtgggtgaaa 720

EP 1 134 286 A2

5 ggccggaacc caagtgaacct ctcttggtcc tcctgcagcc gagatgacct tgaaaacttc 780
 ctcaagtcaa aagtcagcac ctgcttgcta gtcacggacc ccagaagcca gcacacagta 840
 cgccctccgc acaagctgcc gggcatgcac tacagtgcc acgagcagtg ccagatcctg 900
 tttggcatga atgccacct ctgcagaaac atggagcatc taatgtgtgc tggactgtgg 960
 tgcttgtag aaggagacac atcctgcaag accaagctgg accctccct ggatggcacc 1020
 gagtgtgggg cagacaagtg gtgcgcgcgc ggggagtgcg tgagcaagac gcccatcccg 1080
 gagcatgtgg acggagactg gagcccgctg ggcgcctgga gcatgtgcag ccgaacatgt 1140
 gggacgggag cccgcttccg gcagaggaat tgtgacaacc cccccctgg gcctggaggc 1200
 10 acacactgcc cgggtgccag tgtagaacat gcggtctgcg agaacctgcc ctgccccaaag 1260
 ggtctgcccc gcttccggga ccagcagtcg caggcacacg accggctgag cccaagaag 1320
 aaaggcctgc tgacagccgt ggtggttgac gataagccat gtgaactcta ctgctcgccc 1380
 ctcggaagag agtccccact gctggtggcc gacagggtcc tggacggtac accctgcggg 1440
 ccctacgaga ctgatctctg cgtgcacggc aagtgccaga aaatcggtg tgacggcatc 1500
 atcggtctg cagccaaaga ggacagatgc ggggtctgca gcggggacgg caagacctgc 1560
 15 cacttggtga aggcgcactt cagccacgcc cgggggacag gttatatcga agctgcctgc 1620
 attcctgctg gactcggag gatccgtgtg gtggaggata aacctgcccc cagctttctg 1680
 ggtaaaacac aaatgact 1698

20 <210> 4
 <211> 2675
 <212> DNA
 <213> Human

25 <400> 4
 atgtgtgacg gcgcccctgct gectccgctc gtcctgccc tgctgctgct gctgggtttgg 60
 ggactggacc cgggcacagc tgtcggcgac gcggcgccg acgtggaggt ggtgctccc 120
 tggcgggtgc gccccgacga cgtgcacctg ccgcccgtgc ccgcagcccc cgggccccga 180
 cggcgggcac gccccgcac gccccagcc gccccgcgc cccggcccgg agagcgcgcc 240
 ctgctgctgc acctgcgggc cttcgggcgc gacctgtacc ttcagctgcg ccgcgacctg 300
 30 cgcttctctg cccgaggctt cgaggtggag gaggcgggcg cggcccggcg ccgcggccgc 360
 cccgcggagc tgtgcttcta ctcgggccgt gtgctcggcc accccggctc cctcgtctcg 420
 ctcagcgect gcggcgccgc gggcgccctg gttggcctca ttcagcttgg gcaggagcag 480
 gtgctaatac agccctcaa caactcccag ggccattca gtggacgaga acatctgatc 540
 aggcgcaaat ggtccttgac ccccagccct tctgctgagg cccagagacc tgagcagctc 600
 tgcaagggtc taacagaaaa gaagaagccg acgtggggca ggcctttgcg ggactggcg 660
 35 gagcggagga acgctatccg gctcaccagc gagcacacgg tggagacctt ggtggtggcc 720
 gacgcccaga tgggtcagta ccacggggcc gaggtgccc agaggttcat cctgacctgc 780
 atgaacatgg tatacaatat gtttcagcac cagagcctgg ggattaaaat taacattcaa 840
 gtgaccaagc ttgtcctgct acgacaacgt cccgctaagt tgtccattgg gcaccatggt 900
 gagcggctcc tggagagctt cgtcactggc agaacgagga gtatggagga gcgcgatacc 960
 40 tcggcaataa ccaggttccc ggcgggaagg acgaccgcgc cctggtggat gctgctgtgt 1020
 ttgtgaccag gacagatttc tgtgtacaca aagatgaacc gtgtgacact gttggaattg 1080
 ctacttagg aggtgtgtgc agtgctaaga ggaagtgtgt gcttgccgaa gacaatggtc 1140
 tcaatttggc ctttaccatc gcccatgagc tgggcccaca cttgggcatg aaccacgacg 1200
 atgaccactc atcttgcgct ggcaggctcc acatcatgtc aggagagtgg gtgaaaggcc 1260
 ggaacccaag tgacctctct tggctcctct gcagccgaga tgacctgaa aacttctca 1320
 45 agtcaaaagt cagcacctgc ttgctagtc cggaccccag aagccagcac acagtacgcc 1380
 tcccgcacaa gctgcggggc atgcactaca gtgccaacga gcagtgccag atcctggttg 1440
 gcatgaatgc caccttctgc agaaacatgg agcatctaag gtgtgctgga ctgtggtgac 1500
 tggtagaagg agacacatcc tgcaagacca agctggaccc tcccctggat ggcaccgagt 1560
 gtggggcaga caagtgtgct cgcgcggggg agtgctgag caagacgccc atcccgagc 1620
 atgtggacgg agactggagc ccgtggggcg cctggagcat gtgcagccga acatgtggga 1680
 50 cgggagcccg cttccggcag aggaaatgtg acaaccccc cctggggcct ggaggcacac 1740
 actgcccggg tgccagtgtg gaacatgcgg tctgcgagaa cctgcccctg cccaagggtc 1800
 tgcccagctt ccgggaccag cagtgcacgg cacacgacc gctgagcccc aagaagaaag 1860
 gcttgctgag agcgtggtg gttgacgata agccatgtga actctactgc tcgcccctcg 1920
 ggaaggagtc cccactgctg gtggccgaca gggctcctgga cggtagaccc tgcgggccct 1980
 55 acgagactga tctctgcgtg cacggcaagt gccagaaaat cggctgtgac ggcacatcg 2040
 ggtctgcagc caaaggaggac agatgcgggg tctgcagcgg ggacggcaag acctgccact 2100

EP 1 134 286 A2

```

5  tgggtgaaggg cgacttcagc cagcccccggg ggacagggtta tatcgaagct gccgtcattc 2160
   ctgctggagc tcggaggatc cgtgtgggtg aggataaacc tgcccacagc tttctggctc 2220
   tcaaagactc gggtaagggg tccatcaaca gtgactggaa gatagagctc cccggagagt 2280
   tccagattgc aggcaaacct gttcgctatg tgagaagggg gctgtgggag aagatctctg 2340
   ccaagggacc aaccaaacta ccgctgcact tgatgggtgtt gttatttcac gaccaagatt 2400
   atggaattca ttatgaatac actgttcctg taaaccgcac tgcggaaaaat caaagcgaac 2460
   cagaaaaacc gcaggactct ttgttcactt ggacccacag cggctgggaa ggggtgcagt 2520
   tgcagtgcgg cggaggggag cgcagaacca tcgtttcgtg tacacggatt gtcaacaaga 2580
10 ccccaacttt ggtgaacgac agtgactgcc ctcaagcaag ccgcccagag cccaggtcc 2640
   gaaggtgcaa cttgcacccc tgccagtcac ggtaa 2675

```

```

15 <210> 5
   <211> 745
   <212> PRT
   <213> Human

```

```

20 <400> 5
   Met Cys Asp Gly Ala Leu Leu Pro Pro Leu Val Leu Pro Val Leu Leu
      1          5          10          15
   Leu Leu Val Trp Gly Leu Asp Pro Gly Thr Ala Val Gly Asp Ala Ala
      20          25          30
   Ala Asp Val Glu Val Val Leu Pro Trp Arg Val Arg Pro Asp Asp Val
25      35          40          45
   His Leu Pro Pro Leu Pro Ala Ala Pro Gly Pro Arg Arg Arg Arg Arg
      50          55          60
   Pro Arg Thr Pro Pro Ala Ala Pro Arg Ala Arg Pro Gly Glu Arg Ala
30      65          70          75          80
   Leu Leu Leu His Leu Pro Ala Phe Gly Arg Asp Leu Tyr Leu Gln Leu
      85          90          95
   Arg Arg Asp Leu Arg Phe Leu Ser Arg Gly Phe Glu Val Glu Glu Ala
35      100         105         110
   Gly Ala Ala Arg Arg Arg Gly Arg Pro Ala Glu Leu Cys Phe Tyr Ser
      115         120         125
   Gly Arg Val Leu Gly His Pro Gly Ser Leu Val Ser Leu Ser Ala Cys
40      130         135         140
   Gly Ala Ala Gly Gly Leu Val Gly Leu Ile Gln Leu Gly Gln Glu Gln
      145         150         155         160
45 Val Leu Ile Gln Pro Leu Asn Asn Ser Gln Gly Pro Phe Ser Gly Arg
      165         170         175
   Glu His Leu Ile Arg Arg Lys Trp Ser Leu Thr Pro Ser Pro Ser Ala
      180         185         190
50 Glu Ala Gln Arg Pro Glu Gln Leu Cys Lys Val Leu Thr Glu Lys Lys
      195         200         205
   Lys Pro Thr Trp Gly Arg Pro Ser Arg Asp Trp Arg Glu Arg Arg Asn
55      210         215         220

```

EP 1 134 286 A2

	Ala	Ile	Arg	Leu	Thr	Ser	Glu	His	Thr	Val	Glu	Thr	Leu	Val	Val	Ala	225	230	235	240
5	Asp	Ala	Asp	Met	Val	Gln	Tyr	His	Gly	Ala	Glu	Ala	Ala	Gln	Arg	Phe	245	250	255	
	Ile	Leu	Thr	Val	Met	Asn	Met	Val	Tyr	Asn	Met	Phe	Gln	His	Gln	Ser	260	265	270	
10	Leu	Gly	Ile	Lys	Ile	Asn	Ile	Gln	Val	Thr	Lys	Leu	Val	Leu	Leu	Arg	275	280	285	
	Gln	Arg	Pro	Ala	Lys	Leu	Ser	Ile	Gly	His	His	Gly	Glu	Arg	Ser	Leu	290	295	300	
15	Glu	Ser	Phe	Cys	His	Trp	Gln	Asn	Glu	Glu	Tyr	Gly	Gly	Ala	Arg	Tyr	305	310	315	320
	Leu	Gly	Asn	Asn	Gln	Val	Pro	Gly	Gly	Lys	Asp	Asp	Pro	Pro	Leu	Val	325	330	335	
20	Asp	Ala	Ala	Val	Phe	Val	Thr	Arg	Thr	Asp	Phe	Cys	Val	His	Lys	Asp	340	345	350	
	Glu	Pro	Cys	Asp	Thr	Val	Gly	Ile	Ala	Tyr	Leu	Gly	Gly	Val	Cys	Ser	355	360	365	
25	Ala	Lys	Arg	Lys	Cys	Val	Leu	Ala	Glu	Asp	Asn	Gly	Leu	Asn	Leu	Ala	370	375	380	
	Phe	Thr	Ile	Ala	His	Glu	Leu	Gly	His	Asn	Leu	Gly	Met	Asn	His	Asp	385	390	395	400
30	Asp	Asp	His	Ser	Ser	Cys	Ala	Gly	Arg	Ser	His	Ile	Met	Ser	Gly	Glu	405	410	415	
	Trp	Val	Lys	Gly	Arg	Asn	Pro	Ser	Asp	Leu	Ser	Trp	Ser	Ser	Cys	Ser	420	425	430	
35	Arg	Asp	Asp	Leu	Glu	Asn	Phe	Leu	Lys	Ser	Lys	Val	Ser	Thr	Cys	Leu	435	440	445	
	Leu	Val	Thr	Asp	Pro	Arg	Ser	Gln	His	Thr	Val	Arg	Leu	Pro	His	Lys	450	455	460	
40	Leu	Pro	Gly	Met	His	Tyr	Ser	Ala	Asn	Glu	Gln	Cys	Gln	Ile	Leu	Phe	465	470	475	480
	Gly	Met	Asn	Ala	Thr	Phe	Cys	Arg	Asn	Met	Glu	His	Leu	Met	Cys	Ala	485	490	495	
45	Gly	Leu	Trp	Cys	Leu	Val	Glu	Gly	Asp	Thr	Ser	Cys	Lys	Thr	Lys	Leu	500	505	510	
	Asp	Pro	Pro	Leu	Asp	Gly	Thr	Glu	Cys	Gly	Ala	Asp	Lys	Trp	Cys	Arg	515	520	525	
50	Ala	Gly	Glu	Cys	Val	Ser	Lys	Thr	Pro	Ile	Pro	Glu	His	Val	Asp	Gly	530	535	540	
55																				

EP 1 134 286 A2

Asp Trp Ser Pro Trp Gly Ala Trp Ser Met Cys Ser Arg Thr Cys Gly
 545 550 555 560
 5 Thr Gly Ala Arg Phe Arg Gln Arg Lys Cys Asp Asn Pro Pro Pro Gly
 565 570 575
 Pro Gly Gly Thr His Cys Pro Gly Ala Ser Val Glu His Ala Val Cys
 580 585 590
 10 Glu Asn Leu Pro Cys Pro Lys Gly Leu Pro Ser Phe Arg Asp Gln Gln
 595 600 605
 Cys Gln Ala His Asp Arg Leu Ser Pro Lys Lys Lys Gly Leu Leu Thr
 610 615 620
 15 Ala Val Val Val Asp Asp Lys Pro Cys Glu Leu Tyr Cys Ser Pro Leu
 625 630 635 640
 Gly Lys Glu Ser Pro Leu Leu Val Ala Asp Arg Val Leu Asp Gly Thr
 645 650 655
 20 Pro Cys Gly Pro Tyr Glu Thr Asp Leu Cys Val His Gly Lys Cys Gln
 660 665 670
 Lys Ile Gly Cys Asp Gly Ile Ile Gly Ser Ala Ala Lys Glu Asp Arg
 675 680 685
 25 Cys Gly Val Cys Ser Gly Asp Gly Lys Thr Cys His Leu Val Lys Gly
 690 695 700
 Asp Phe Ser His Ala Arg Gly Thr Gly Tyr Ile Glu Ala Ala Val Ile
 705 710 715 720
 30 Pro Ala Gly Ala Arg Arg Ile Arg Val Val Glu Asp Lys Pro Ala His
 725 730 735
 35 Ser Phe Leu Gly Lys Thr Gln Met Thr
 740 745
 40 <210> 6
 <211> 635
 <212> PRT
 <213> Human
 <400> 6
 45 Met Cys Asp Gly Ala Leu Leu Pro Pro Leu Val Leu Pro Val Leu Leu
 1 5 10 15
 Leu Leu Val Trp Gly Leu Asp Pro Gly Thr Ala Val Gly Asp Ala Ala
 20 25 30
 50 Ala Asp Val Glu Val Val Leu Pro Trp Arg Val Arg Pro Asp Asp Val
 35 40 45
 His Leu Pro Pro Leu Pro Ala Ala Pro Gly Pro Arg Arg Arg Arg Arg
 50 55 60
 55 Pro Arg Thr Pro Pro Ala Ala Pro Arg Ala Arg Pro Gly Glu Arg Ala
 65 70 75 80

EP 1 134 286 A2

5 Leu Leu Leu His Leu Pro Ala Phe Gly Arg Asp Leu Tyr Leu Gln Leu
 85 90 95
 Arg Arg Asp Leu Arg Phe Leu Ser Arg Gly Phe Glu Val Glu Glu Ala
 100 105 110
 Gly Ala Ala Arg Arg Arg Gly Arg Pro Ala Glu Leu Cys Phe Tyr Ser
 115 120 125
 10 Gly Arg Val Leu Gly His Pro Gly Ser Leu Val Ser Leu Ser Ala Cys
 130 135 140
 Gly Ala Ala Gly Gly Leu Val Gly Leu Ile Gln Leu Gly Gln Glu Gln
 145 150 155 160
 15 Val Leu Ile Gln Pro Leu Asn Asn Ser Gln Gly Pro Phe Ser Gly Arg
 165 170 175
 Glu His Leu Ile Arg Arg Lys Trp Ser Leu Thr Pro Ser Pro Ser Ala
 180 185 190
 Glu Ala Gln Arg Pro Glu Gln Leu Cys Lys Val Leu Thr Glu Lys Lys
 195 200 205
 25 Lys Pro Thr Trp Gly Arg Pro Ser Arg Asp Trp Arg Glu Arg Arg Asn
 210 215 220
 Ala Ile Arg Leu Thr Ser Glu His Thr Val Glu Thr Leu Val Val Ala
 225 230 235 240
 30 Asp Ala Asp Met Val Gln Tyr His Gly Ala Glu Ala Ala Gln Arg Phe
 245 250 255
 Ile Leu Thr Val Met Asn Met Val Tyr Asn Met Phe Gln His Gln Ser
 260 265 270
 35 Leu Gly Ile Lys Ile Asn Ile Gln Val Thr Lys Leu Val Leu Leu Arg
 275 280 285
 Gln Arg Pro Ala Lys Leu Ser Ile Gly His His Gly Glu Arg Ser Leu
 290 295 300
 40 Glu Ser Phe Cys His Trp Gln Asn Glu Glu Tyr Gly Gly Ala Arg Tyr
 305 310 315 320
 Leu Gly Asn Asn Gln Val Pro Gly Gly Lys Asp Asp Pro Pro Leu Val
 325 330 335
 45 Asp Ala Ala Val Phe Val Thr Arg Thr Asp Phe Cys Val His Lys Asp
 340 345 350
 Glu Pro Cys Asp Thr Val Gly Ile Ala Tyr Leu Gly Gly Val Cys Ser
 355 360 365
 50 Ala Lys Arg Lys Cys Val Leu Ala Glu Asp Asn Gly Leu Asn Leu Ala
 370 375 380
 Phe Thr Ile Ala His Glu Leu Gly His Asn Leu Gly Met Asn His Asp
 385 390 395 400

EP 1 134 286 A2

Asp Asp His Ser Ser Cys Ala Gly Arg Ser His Ile Met Ser Gly Glu
 405 410 415
 5 Trp Val Lys Gly Arg Asn Pro Ser Asp Leu Ser Trp Ser Ser Cys Ser
 420 425 430
 Arg Asp Asp Leu Glu Asn Phe Leu Asn Pro Gly Pro Gly Gly Thr His
 435 440 445
 10 Cys Pro Gly Ala Ser Val Glu His Ala Val Cys Glu Asn Leu Pro Cys
 450 455 460
 Pro Lys Gly Leu Pro Ser Phe Arg Asp Gln Gln Cys Gln Ala His Asp
 465 470 475 480
 15 Arg Leu Ser Pro Lys Lys Lys Gly Leu Leu Thr Ala Val Val Val Asp
 485 490 495
 Asp Lys Pro Cys Glu Leu Tyr Cys Ser Pro Leu Gly Lys Glu Ser Pro
 500 505 510
 20 Leu Leu Val Ala Asp Arg Val Leu Asp Gly Thr Pro Cys Gly Pro Tyr
 515 520 525
 Glu Thr Asp Leu Cys Val His Gly Lys Cys Gln Lys Ile Gly Cys Asp
 530 535 540
 25 Gly Ile Ile Gly Ser Ala Ala Lys Glu Asp Arg Cys Gly Val Cys Ser
 545 550 555 560
 Gly Asp Gly Lys Thr Cys His Leu Val Lys Gly Asp Phe Ser His Ala
 565 570 575
 30 Arg Gly Thr Val Lys Asn Asp Leu Cys Thr Lys Val Ser Thr Cys Val
 580 585 590
 Met Ala Glu Ala Val Pro Lys Cys Phe Ser Cys Tyr Ile Glu Ala Ala
 595 600 605
 35 Val Ile Pro Ala Gly Ala Arg Arg Ile Arg Val Val Glu Asp Lys Pro
 610 615 620
 40 Ala His Ser Phe Leu Gly Lys Thr Gln Met Thr
 625 630 635
 45 <210> 7
 <211> 566
 <212> PRT
 <213> Human
 <400> 7
 50 Met Cys Asp Gly Ala Leu Leu Pro Pro Leu Val Leu Pro Val Leu Leu
 1 5 10 15
 Leu Leu Val Trp Gly Leu Asp Pro Gly Thr Glu Lys Lys Lys Pro Thr
 20 25 30
 55 Trp Gly Arg Pro Ser Arg Asp Trp Arg Glu Arg Arg Asn Ala Ile Arg

EP 1 134 286 A2

	35		40		45
5	Leu Thr Ser Glu His Thr Val Glu Thr Leu Val Val Ala Asp Ala Asp	50	55	60	
	Met Val Gln Tyr His Gly Ala Glu Ala Ala Gln Arg Phe Ile Leu Thr	65	70	75	80
10	Val Met Asn Met Val Tyr Asn Met Phe Gln His Gln Ser Leu Gly Ile	85	90	95	
	Lys Ile Asn Ile Gln Val Thr Lys Leu Val Leu Leu Arg Gln Arg Pro	100	105	110	
15	Ala Lys Leu Ser Ile Gly His His Gly Glu Arg Ser Leu Glu Ser Phe	115	120	125	
	Cys His Trp Gln Asn Lys Glu Tyr Gly Gly Ala Arg Tyr Leu Gly Asn	130	135	140	
20	Asn Gln Val Pro Gly Gly Lys Asp Asp Pro Pro Leu Val Asp Ala Ala	145	150	155	160
	Val Phe Val Thr Arg Thr Asp Phe Cys Val His Lys Asp Glu Pro Cys	165	170	175	
25	Asp Thr Val Gly Ile Ala Tyr Leu Gly Gly Val Cys Ser Ala Lys Arg	180	185	190	
	Lys Cys Val Leu Ala Glu Asp Asn Gly Leu Asn Leu Ala Phe Thr Ile	195	200	205	
30	Ala His Glu Leu Gly His Asn Leu Gly Met Asn His Asp Asp Asp His	210	215	220	
	Ser Ser Cys Ala Gly Arg Ser His Ile Met Ser Gly Glu Trp Val Lys	225	230	235	240
35	Gly Arg Asn Pro Ser Asp Leu Ser Trp Ser Ser Cys Ser Arg Asp Asp	245	250	255	
	Leu Glu Asn Phe Leu Lys Ser Lys Val Ser Thr Cys Leu Leu Val Thr	260	265	270	
40	Asp Pro Arg Ser Gln His Thr Val Arg Leu Pro His Lys Leu Pro Gly	275	280	285	
	Met His Tyr Ser Ala Asn Glu Gln Cys Gln Ile Leu Phe Gly Met Asn	290	295	300	
45	Ala Thr Phe Cys Arg Asn Met Glu His Leu Met Cys Ala Gly Leu Trp	305	310	315	320
	Cys Leu Val Glu Gly Asp Thr Ser Cys Lys Thr Lys Leu Asp Pro Pro	325	330	335	
50	Leu Asp Gly Thr Glu Cys Gly Ala Asp Lys Trp Cys Arg Ala Gly Glu	340	345	350	
55	Cys Val Ser Lys Thr Pro Ile Pro Glu His Val Asp Gly Asp Trp Ser				

EP 1 134 286 A2

	355		360		365
5	Pro Trp Gly Ala Trp Ser Met Cys Ser Arg Thr Cys Gly Thr Gly Ala 370 375 380				
	Arg Phe Arg Gln Arg Lys Cys Asp Asn Pro Pro Gly Pro Gly Gly 385 390 400				
10	Thr His Cys Pro Gly Ala Ser Val Glu His Ala Val Cys Glu Asn Leu 405 410 415				
	Pro Cys Pro Lys Gly Leu Pro Ser Phe Arg Asp Gln Gln Cys Gln Ala 420 425 430				
15	His Asp Arg Leu Ser Pro Lys Lys Lys Gly Leu Leu Thr Ala Val Val 435 440 445				
	Val Asp Asp Lys Pro Cys Glu Leu Tyr Cys Ser Pro Leu Gly Lys Glu 450 455 460				
20	Ser Pro Leu Leu Val Ala Asp Arg Val Leu Asp Gly Thr Pro Cys Gly 465 470 475 480				
	Pro Tyr Glu Thr Asp Leu Cys Val His Gly Lys Cys Gln Lys Ile Gly 485 490 495				
25	Cys Asp Gly Ile Ile Gly Ser Ala Ala Lys Glu Asp Arg Cys Gly Val 500 505 510				
	Cys Ser Gly Asp Gly Lys Thr Cys His Leu Val Lys Gly Asp Phe Ser 515 520 525				
30	His Ala Arg Gly Thr Gly Tyr Ile Glu Ala Ala Val Ile Pro Ala Gly 530 535 540				
	Ala Arg Arg Ile Arg Val Val Glu Asp Lys Pro Ala His Ser Phe Leu 545 550 555 560				
35	Gly Lys Thr Gln Met Thr 565				
40	<210> 8 <211> 891 <212> PRT <213> Human				
45	<400> 8 Met Cys Asp Gly Ala Leu Leu Pro Pro Leu Val Leu Pro Val Leu Leu 1 5 10 15				
	Leu Leu Val Trp Gly Leu Asp Pro Gly Thr Ala Val Gly Asp Ala Ala 20 25 30				
50	Ala Asp Val Glu Val Val Leu Pro Trp Arg Val Arg Pro Asp Asp Val 35 40 45				
	His Leu Pro Pro Leu Pro Ala Ala Pro Gly Pro Arg Arg Arg Arg 50 55 60				
55					

EP 1 134 286 A2

	Pro	Arg	Thr	Pro	Pro	Ala	Ala	Pro	Arg	Ala	Arg	Pro	Gly	Glu	Arg	Ala	65	70	75	80
5	Leu	Leu	Leu	His	Leu	Pro	Ala	Phe	Gly	Arg	Asp	Leu	Tyr	Leu	Gln	Leu	85	90	95	
	Arg	Arg	Asp	Leu	Arg	Phe	Leu	Ser	Arg	Gly	Phe	Glu	Val	Glu	Glu	Ala	100	105	110	
10	Gly	Ala	Ala	Arg	Arg	Arg	Gly	Arg	Pro	Ala	Glu	Leu	Cys	Phe	Tyr	Ser	115	120	125	
	Gly	Arg	Val	Leu	Gly	His	Pro	Gly	Ser	Leu	Val	Ser	Leu	Ser	Ala	Cys	130	135	140	
15	Gly	Ala	Ala	Gly	Gly	Leu	Val	Gly	Leu	Ile	Gln	Leu	Gly	Gln	Glu	Gln	145	150	155	160
	Val	Leu	Ile	Gln	Pro	Leu	Asn	Asn	Ser	Gln	Gly	Pro	Phe	Ser	Gly	Arg	165	170	175	
20	Glu	His	Leu	Ile	Arg	Arg	Lys	Trp	Ser	Leu	Thr	Pro	Ser	Pro	Ser	Ala	180	185	190	
	Glu	Ala	Gln	Arg	Pro	Glu	Gln	Leu	Cys	Lys	Val	Leu	Thr	Glu	Lys	Lys	195	200	205	
25	Lys	Pro	Thr	Trp	Gly	Arg	Pro	Leu	Arg	Asp	Trp	Arg	Glu	Arg	Arg	Asn	210	215	220	
	Ala	Ile	Arg	Leu	Thr	Ser	Glu	His	Thr	Val	Glu	Thr	Leu	Val	Val	Ala	225	230	235	240
	Asp	Ala	Asp	Met	Val	Gln	Tyr	His	Gly	Ala	Glu	Ala	Ala	Gln	Arg	Phe	245	250	255	
35	Ile	Leu	Thr	Val	Met	Asn	Met	Val	Tyr	Asn	Met	Phe	Gln	His	Gln	Ser	260	265	270	
	Leu	Gly	Ile	Lys	Ile	Asn	Ile	Gln	Val	Thr	Lys	Leu	Val	Leu	Leu	Arg	275	280	285	
40	Gln	Arg	Pro	Ala	Lys	Leu	Ser	Ile	Gly	His	His	Gly	Glu	Arg	Ser	Leu	290	295	300	
	Glu	Ser	Phe	Cys	His	Trp	Gln	Asn	Glu	Glu	Tyr	Gly	Gly	Ala	Arg	Tyr	305	310	315	320
45	Leu	Gly	Asn	Asn	Gln	Val	Pro	Gly	Gly	Lys	Asp	Asp	Pro	Pro	Leu	Val	325	330	335	
	Asp	Ala	Ala	Val	Phe	Val	Thr	Arg	Thr	Asp	Phe	Cys	Val	His	Lys	Asp	340	345	350	
50	Glu	Pro	Cys	Asp	Thr	Val	Gly	Ile	Ala	Tyr	Leu	Gly	Gly	Val	Cys	Ser	355	360	365	
	Ala	Lys	Arg	Lys	Cys	Val	Leu	Ala	Glu	Asp	Asn	Gly	Leu	Asn	Leu	Ala	370	375	380	
55																				

EP 1 134 286 A2

	Phe	Thr	Ile	Ala	His	Glu	Leu	Gly	His	Asn	Leu	Gly	Met	Asn	His	Asp	
	385					390					395					400	
5	Asp	Asp	His	Ser	Ser	Cys	Ala	Gly	Arg	Ser	His	Ile	Met	Ser	Gly	Glu	
					405					410					415		
	Trp	Val	Lys	Gly	Arg	Asn	Pro	Ser	Asp	Leu	Ser	Trp	Ser	Ser	Cys	Ser	
				420					425					430			
10	Arg	Asp	Asp	Leu	Glu	Asn	Phe	Leu	Lys	Ser	Lys	Val	Ser	Thr	Cys	Leu	
			435					440					445				
	Leu	Val	Thr	Asp	Pro	Arg	Ser	Gln	His	Thr	Val	Arg	Leu	Pro	His	Lys	
			450				455					460					
15	Leu	Pro	Gly	Met	His	Tyr	Ser	Ala	Asn	Glu	Gln	Cys	Gln	Ile	Leu	Phe	
	465					470					475					480	
	Gly	Met	Asn	Ala	Thr	Phe	Cys	Arg	Asn	Met	Glu	His	Leu	Met	Cys	Ala	
20					485					490					495		
	Gly	Leu	Trp	Cys	Leu	Val	Glu	Gly	Asp	Thr	Ser	Cys	Lys	Thr	Lys	Leu	
				500					505					510			
25	Asp	Pro	Pro	Leu	Asp	Gly	Thr	Glu	Cys	Gly	Ala	Asp	Lys	Trp	Cys	Arg	
			515					520					525				
	Ala	Gly	Glu	Cys	Val	Ser	Lys	Thr	Pro	Ile	Pro	Glu	His	Val	Asp	Gly	
			530				535					540					
30	Asp	Trp	Ser	Pro	Trp	Gly	Ala	Trp	Ser	Met	Cys	Ser	Arg	Thr	Cys	Gly	
	545					550					555					560	
	Thr	Gly	Ala	Arg	Phe	Arg	Gln	Arg	Lys	Cys	Asp	Asn	Pro	Pro	Pro	Gly	
					565					570						575	
35	Pro	Gly	Gly	Thr	His	Cys	Pro	Gly	Ala	Ser	Val	Glu	His	Ala	Val	Cys	
				580					585					590			
	Glu	Asn	Leu	Pro	Cys	Pro	Lys	Gly	Leu	Pro	Ser	Phe	Arg	Asp	Gln	Gln	
			595					600					605				
40	Cys	Gln	Ala	His	Asp	Arg	Leu	Ser	Pro	Lys	Lys	Lys	Gly	Leu	Leu	Thr	
		610					615					620					
	Ala	Val	Val	Val	Asp	Asp	Lys	Pro	Cys	Glu	Leu	Tyr	Cys	Ser	Pro	Leu	
	625					630					635					640	
45	Gly	Lys	Glu	Ser	Pro	Leu	Leu	Val	Ala	Asp	Arg	Val	Leu	Asp	Gly	Thr	
					645					650					655		
	Pro	Cys	Gly	Pro	Tyr	Glu	Thr	Asp	Leu	Cys	Val	His	Gly	Lys	Cys	Gln	
				660					665					670			
50	Lys	Ile	Gly	Cys	Asp	Gly	Ile	Ile	Gly	Ser	Ala	Ala	Lys	Glu	Asp	Arg	
			675					680					685				
	Cys	Gly	Val	Cys	Ser	Gly	Asp	Gly	Lys	Thr	Cys	His	Leu	Val	Lys	Gly	
55		690					695					700					

EP 1 134 286 A2

Asp Phe Ser His Ala Arg Gly Thr Gly Tyr Ile Glu Ala Ala Val Ile
 705 710 715 720
 5 Pro Ala Gly Ala Arg Arg Ile Arg Val Val Glu Asp Lys Pro Ala His
 725 730 735
 Ser Phe Leu Ala Leu Lys Asp Ser Gly Lys Gly Ser Ile Asn Ser Asp
 740 745 750
 10 Trp Lys Ile Glu Leu Pro Gly Glu Phe Gln Ile Ala Gly Thr Thr Val
 755 760 765
 Arg Tyr Val Arg Arg Gly Leu Trp Glu Lys Ile Ser Ala Lys Gly Pro
 770 775 780
 15 Thr Lys Leu Pro Leu His Leu Met Val Leu Leu Phe His Asp Gln Asp
 785 790 795 800
 Tyr Gly Ile His Tyr Glu Tyr Thr Val Pro Val Asn Arg Thr Ala Glu
 805 810 815
 20 Asn Gln Ser Glu Pro Glu Lys Pro Gln Asp Ser Leu Phe Ile Trp Thr
 820 825 830
 His Ser Gly Trp Glu Gly Cys Ser Val Gln Cys Gly Gly Glu Arg
 835 840 845
 25 Arg Thr Ile Val Ser Cys Thr Arg Ile Val Asn Lys Thr Pro Thr Leu
 850 855 860
 Val Asn Asp Ser Asp Cys Pro Gln Ala Ser Arg Pro Glu Pro Gln Val
 865 870 875 880
 30 Arg Arg Cys Asn Leu His Pro Cys Gln Ser Arg
 885 890
 35 <210> 9
 <211> 1966
 <212> DNA
 <213> Human
 40 <400> 9
 ccccgccgag ctgtgcttct actcgggccc tgtgctcggc caccgccggt ccctcgtctc 60
 gctcagcgcc tgcggcgccg ccggcgccct ggttggcctc attcagcttg gccaggagca 120
 ggtgctaata cagccctcca acaactccca gggcccatc agtggacgag aacatctgat 180
 caggcgcaaa tggtccttga ccccgagccc ttctgctgag gccagagac ctgagcagct 240
 45 ctgcaagggtt ctaacagaaa agaagaagcc gacgtggggc aggcctttgc gggactggcg 300
 ggagcggagg aacgctatcc ggctcaccag cgagcacacg gtggagaccc tgggtgggtggc 360
 cgacgcccgc atggtgcagt accacggggc cgaggctgcc cagaggttca tcctgaccgt 420
 catgaacatg gtatacaata tgtttcagca ccagagcctg gggattaaaa ttaacattca 480
 agtgaccaag cttgtcctgc tacgacaacg tcccgctaag ttgtccattg ggcaccatgg 540
 tgagcgggtcc ctggagagct tctgtcactg gcagaacgag gagtatggag gagcgcgata 600
 50 cctcggcaat aaccaggttc ccggcgggaa ggacgacccg cccctgggtg atgctgctgt 660
 gtttgtgacc aggacagatt tctgtgtaca caaatgatga cctgttgaca ctgttggaat 720
 tgcttactta ggagggtgtg gcagtgttaa gaggaagtgt gtgcttgccg aagacaatgg 780
 tctcaatttg gcccttacca tcgcccatag gctggggccac aacttgggca tgaaccacga 840
 cgatgaccac tcattcttgc ctggcaggtc ccacatcatg tcaggagagt gggtgaaagg 900
 55 ccggaaccca agtgacctct cttggtcctc ctgcagccga gatgacctg aaaacttctt 960
 caagtcaaaa gtcagcacct gcttgctagt cacggacccc agaagccagc acacagtacg 1020

```

cctccccgac aagctgccgg gcatgcacta cagtgccaac gagcagtgcc agatcctgtt 1080
tggcatgaat gccaccttct gcagaaacat ggagcatcta atgtgtgctg gactgtggtg 1140
5 cctggtagaa ggagacacat cctgcaagac caagctggac cctcccctgg atggcaccga 1200
gtgtggggca gacaagtgtt gccgcgcggg ggagtgcgtg agcaagacgc ccatcccgga 1260
gcatgtggac ggagactgga gcccggtggg cgcttgagc atgtgcagcc gaacatgtgg 1320
gacgggagcc cgcttccggc agaggaaatg tgacaacccc ccccctgggc ctggaggcac 1380
acactgcccg ggtgccagtg tagaacatgc ggtctgcgag aacctgccct gcccgaagg 1440
10 tctgcccagc ttccgggacc agcagtgcc aagcacacgc cggctgagcc ccaagaagaa 1500
aggcctgctg acagccgtgg tggttgacga taagccatgt gaactctact gctcgcccct 1560
cgggaaggag tccccactgc tgggtggcga cagggtcctg gacgggtacac cctgcgggcc 1620
ctacgagact gatctctgcg tgcacggcaa gtgccagaaa atcggctgtg acggcatcat 1680
cgggtctgca gccaaaagg acagatgcgg ggtctgcagc ggggacggca agacctgcca 1740
15 cttggtgaag ggcgacttca gccacgcccg ggggacaggt tatatcgaag ctgccgtcat 1800
tctgtctgga gctcggagga tccgtgtggt ggaggataaa cctgccaca gctttctggg 1860
taaaacacaa atgacttgac tcaccattta tgtgttgaga atcgattttg atgatcagtc 1920
tggtaaattg gttcagtgtc aaaaaaaaaa aaaaaaaaaa aaaaaa 1966

```

```

20 <210> 10
    <211> 46
    <212> DNA
    <213> Human

```

```

25 <400> 10
    tcacttgta tctctgtcct ttagtgcacc cagaaagctg tgggca 46

```

```

30 <210> 11
    <211> 20
    <212> DNA
    <213> Human

```

```

35 <400> 11
    ggacgttgta gtagcaggac 20

```

```

40 <210> 12
    <211> 26
    <212> DNA
    <213> Human

```

```

45 <400> 12
    ggaattcggg taccatgtgt gacggc 26

```

50 Claims

1. An isolated polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of:

- 55 (a) a nucleotide sequence having at least 80% identity to a nucleotide sequence encoding an ADAMTS-J1 polypeptide of SEQ ID NO: 5, 6, 7, or 8, or a metalloproteinase, disintegrin domain, prodomain, or thrombospondin (TSP) domain thereof;
- (b) a nucleotide sequence of at least 15 contiguous nucleotides that hybridizes under stringent conditions to a polynucleotide molecule of SEQ ID NO: 1, 2, 3, or 4; and

(c) the complement of the nucleotide sequence of (a) or (b).

2. An isolated polynucleotide molecule of claim 1, wherein said polynucleotide sequence comprises the ADAMTS-J1 polypeptide encoding sequence of SEQ ID NO: 1, 2, 3, or 4, or a metalloproteinase, disintegrin domain, pro-domain, or thrombospondin (TSP) domain encoding sequence thereof.
3. A polypeptide encoded by the isolated polynucleotide molecule of claim 1.
4. The polypeptide of claim 3 which comprises an amino acid sequence that is SEQ ID NO: 5, 6, 7, or 8, or a metalloproteinase, disintegrin domain, prodomain, or thrombospondin (TSP) domain thereof.
5. An expression system comprising a DNA or RNA molecule, wherein said expression system is capable of producing an ADAMTS-J1 polypeptide of claim 3 when said expression system is present in a compatible host cell.
6. A host cell comprising the expression system of claim 5.
7. A process for producing an ADAMTS-J1 polypeptide comprising culturing a host cell of claim 6 under conditions sufficient for production of said polypeptide, and recovering the polypeptide from cell culture.
8. An agent selected from the group consisting of an antibody immunospecific for an ADAMTS-J1 polypeptide, an agonist for an ADAMTS-J1 polypeptide, an antagonist for an ADAMTS-J1 polypeptide, and a substrate for an ADAMTS-J1 polypeptide, wherein said polypeptide is the polypeptide of claim 4.
9. Use of an agent according to claim 8 in the manufacture of a medicament for treating a subject in need of altering activity or expression of ADAMTS-J1.
10. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of ADAMTS-J1 in a subject comprising determining presence or absence of a mutation in a nucleotide sequence encoding a polypeptide of claim 3 in the genome of said subject, or analyzing for presence or amount of ADAMTS-J1 expression in a sample derived from said subject.
11. A method for identifying compounds which antagonize, agonize, or bind to ADAMTS-J1 comprising:
 - (a) contacting a candidate compound with cells expressing an ADAMTS-J1 polypeptide of claim 3, or with cell membranes from cells expressing said ADAMTS-J1 polypeptide, or the media conditioned by cells expressing said polypeptide, or a purified composition of said polypeptide; and
 - (b) determining inhibition or stimulation of an ADAMTS-J1 activity, or binding of said candidate compound to said polypeptide.
12. A method for detecting a polynucleotide encoding ADAMTS-J1 in a biological sample containing nucleic acid material comprising:
 - (a) hybridizing an isolated polynucleotide of claim 1 that is specific to ADAMTS-J1 to the nucleic acid material of the biological sample, thereby forming a hybridization complex; and
 - (b) detecting the hybridization complex, wherein presence of the hybridization complex correlates with the presence of the polynucleotide encoding ADAMTS-J1 in the biological sample.
13. A method for identifying a substrate for ADAMTS-J1 comprising contacting a polypeptide comprising an enzymatically active polypeptide of claim 3 with a candidate substrate and determining either conversion of substrate to product or binding of the polypeptide to the substrate.
14. Use of an agent selected from the group consisting of an agonist or antagonist of ADAMTS-J1, a polypeptide of claim 3, and a polynucleotide of claim 1, in the manufacture of medicament for treating arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atheroscle-

rotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock.

15. A pharmaceutical composition for the treatment of arthritis (osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer (such as solid tumor cancer including colon, breast, lung, prostate, brain and hematopoietic malignancies including leukemia and lymphoma), tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock, comprising a therapeutically effective amount of an agent selected from the group consisting of an agonist or antagonist of ADAMTS-J1, a polypeptide of claim 3, and a polynucleotide of claim 1, in combination with a pharmaceutically acceptable carrier.

FIG. 1 Nucleic Acid Sequence of ADAMTS-J1.1 [SEQ ID NO: 1]

atgtgtgacggcgccctgctgcctccgctcgtcctgcccgtgctgctgctggttggggactggacccgggcacagctgtcggngac
 gggcgggcgacgtggagggtgctcccgtggcggtgccccgacgacgtgcacctgccgctgcccgcagccccgggc
 cccgacggcgggcgacgccccgcacgccccagccgccccgcgccccggcgagagcgccctgctgctgcacctgccgg
 ccttcgggcgcgacctgtacctcagctgcgcccgcacctgccttctgtcccaggcttcgaggtggaggaggcgggcgcgccccg
 gcgccccggcgccccgcgagctgtgcttactcgggcccgtgtgctcgccacccccggctccctcgtctcgtcagcgccctgcggcg
 ccgccccggcgccctggtggcctcattcagcttgggcaggagcaggtgctaaccagcccccaacaactcccagggcccattcagtg
 acgagaacatctgatcaggcgcaaatggtcctgacccccagcccttctgtgaggccagagacctgagcagctctgaaggttctaa
 cagaaaagaagaagccgacgtggggcaggccttcggggactggcgggagcgagggaacgctatccggctcaccagcgagcac
 acggtggagaccctggtggtggccgacgcccagacatggtgcagtaccacggggcgaggccgcccagaggttcactctgaccgtcat
 gaacatggtatataatattttcagcaccagagccctggggattaaaattacattcaagtgaacaaagcttgcctgctacgacaacgtcc
 cgtaagtgtccattgggcaccatggtgagcggtccctggagagcttctgtactggcagaacgaggagatggaggagcgcgatac
 ctcggaataaccaggtcccgggcggaaggacgacccgcccctggtggatgctgctgtgttgtgaccaggacagatttctgtgtacac
 aaagatgaaccgtgtgacactgttgaattgcttacttaggaggtgtgtgcagtgtgaagaggaagtgtgtgcttccgaagacaatggt
 ctcaatttggcctttaccatcgccatgagctgggccacaacttggcatgaaccacgacgatgaccactcatcttgcgtggcagggtcc
 cacatcatgtcaggagagtggtgaaaggccggaacccaagtacacctcttggctcctcctgcagccgagatgaccttgaaaacttct
 caagtcaaaagtcagcacctgctgtgtacgacggacccagaagccagcacacagtacgcctcccgacaaagctgccgggcatgc
 actacagtccaacgagcagtgccagatcctgttggcatgaatgccacctctgcagaaacatggagcatctaattgtgtgctggactgt
 ggtgcctggtagaaggagacacatcctgaagaccaagctggacctccctggatggcaccgagtggtgggagacaaagtggtgc
 cgcggggggagtgctgagcaagacgcccacccggagcatgtggacggagactggagcccgtggggcgccctggagcatgtgca
 gccgaacatgtgggacgggagcccgttccggcagaggaaatgtgacaacccccccctgggctggaggcacacactgccggg
 tgccagtgtagaacatgcggintgcgagaacctgccctgcccgaagggtctgccagcttccgggaccagcagtgccaggcacacga
 ccggtgagccccagaagaaggcctgctgacagccgtggtggtgacgataagccatgtgaacttactgctcggccctcgga
 ggagtcccactgctggtggcgacagggcttgacgggtacacctgcgggcccctacgagactgatctctgctgcacggcaagtgc
 cagaaaatcggtgtgacggcatcatcggtctgcagccaaaggagacagatgcggggtctgcagcggggacggcaagacctgcc
 acttggtaaggggcacttcagccacgccccggggacaggttatatgaagctgccgtcattcctgctggagctcggaggatccgtgtg
 gtggaggataaacctgcccacagcttctgggtaaaacacaaatgact

FIG. 2 Nucleic Acid Sequence of ADAMTS-J1.2 [SEQ ID NO: 2]

atgtgtgacggcgccctgctgcctccgctcgctcctgcccgtgctgctgctgctggttggggactggacccgggcacagctgtcggcgac
 gggcgggcgacgtggaggtggtgctcccgtggcgggtgcgccccgacgacgtgcacctgccgcccgtcccgcagccccgggc
 cccgacggcgggcgacgccccgcacgccccagccgccccgcgccccggccggagagcgccctgctgctgcacctgccgg
 ccttcggcgcgacctgtacctcagctgcgcgcgacctgcgcttctgtcccaggcttcgaggtggaggaggcgggcgcgccccg
 gcgcccgcggcgccccgcgagctgtgcttctactcgggcccgtgtgctcgccacccccgctccctcgtctcgtcagcgctgcggcg
 ccgcccgcggcctggttggcctcattcagcttggcaggagcaggtgctaaccagcccctcaacaactcccagggcccattcagtg
 acgagaacatctgatcaggcgcaaatggctcctgacccccagcccttctgctgaggcccagagacctgagcagctctgaaggttcta
 cagaaaagaagaagccgacgtggggcaggccttcgcccggactggcgggagcggaggaacgctatccggctcaccagcgagcac
 acggtggagacctggtggtggcgacccgacatggtgcagtaccaggggcccagggcccagaggttcatctgacctgcat
 gaacatggtatacaatatgttcagcaccagagcctggggattaaaattaacattcaagtaccaagcttgctgctacgacaacgtcc
 cgctaagttgtcattgggcaccatggtgagcggctccctggagagcttctgtcactggcagaacgaggagtatggagggcgcgatac
 ctgcggaataaccaggttcccggcggaaggacgacccgcccctggtggtgctgcccgtgttgaccaggacagatttctgtgtaca
 caaggatgaacctgtgacactgttgaattgcttacttaggaggtgtgtgcagtgtgaagaggaagtgtgtgcttccgaagacaatgg
 tctcaatttggcctttaccatcgcccatgagctgggcccacaacttgggcatgaaccacgacgatgacctcatcttgcgtggcaggtcc
 cacatcatgtcaggagagtggtgaaaggccggaacccaagtacctcttggctcctcctgcagccgagatgacctgaaaacttct
 caacctgggcttgaggcacacactgcccgggtgccagtgtagaacatgcggtctgcgagaacctgccctgccccagggtctgcc
 cagcttccgggaccagcagtgccaggcacacgaccggctgagccccaagaagaaaggcctgctgacagccgtggtggtgacgat
 aagccatgtgaactctactgctgccccctcggaaggagtccttctggtggccgacagggctctggacggtacacctgcgggc
 cctacgagactgatctctgctgcacggcaagtccagaaaaatcggtgtgacggcatcatcggtctgcagccaaaggagacagat
 gcggggtctgcagcggggacggcaagacctgccacttggtgaaggcgacttcagccacgcccggggacagttaagaatgatctct
 gtacgaaggtatccacatgtgtgatggcagaggctgttccaagtgttctcatgttatatcgaagctgccgtcattcctgctggagctcgga
 ggatccgtgtggtggag gataaacctgccacagcttctgggtaaaacacaaatgact

FIG.3 Nucleic Acid Sequence of ADAMTS-J1.3 [SEQ ID NO: 3]

atgtgtgacggcgccctgctgcctccgctcgctcctgcccgtgctgctgctggttggggactggacccgggcacagaaaagaagaa
 gccgacgtggggcaggccttcgcccactggcgggagcggaggaaacgctatccggctcaccagcgagcacacggtggagaccct
 ggtggtggccgacgcccacatggtgcagtaccacggggccgaggccgcccagagggtcatcctgaccgtcatgaacatggtatacaa
 tatgtttcagcaccagagcctggggattaaaattaacattcaagtgaaccaagctgtcctgctacgacaacgtcccgttaagttgtccattg
 ggcacatggtgagcgggtccctggagagcttctgtcactggcagaacaaggagtatggaggagcgcgatacctcggcaataaccag
 gttcccgccgggaaggacgacccgcccctggtgatgctgctgtgtttgtgaccaggacagatttctgtgtacacaaagatgaaccgtgt
 gacactgttggaattgcttacttaggaggtgtgtgcagtgtctaaagggaagtgtgtgcttgcgaagacaatggtctcaattggcctttacc
 atcgcccatgagctgggcccacaacttgggcatgaaccacgacgatgaccactcatctgcgctggcagggtcccacatcatgtcaggag
 agtgggtgaaaggccggaacccaagtacctctcttggctcctcctgcagccgagatgacctgaaaacttcctcaagtcaaaagtcagc
 acctgctgtctagtacggaccccagaagccagcacacagtacgcctcccgacacaagctgccgggcatgactacagtgtccaacga
 gcagtgtccagatcctgttggcatgaatgccaccttctgcagaaacatggagcatctaatgtgtgctggactgtggtgcctggtagaagga
 gacacatcctgcaagaccaagtggaccctccccctggatggcaccgagtggtgggcagacaagtgggtgccgcgccccgggagtgct
 gagcaagacgcccaccccggagcatgtggacgggagactggagcccgtggggcgctggagcatgtgcagccgaacatgtgggacg
 ggagcccgttccggcagaggaaatgtgacaacccccccctgggcctggaggcacacactgcccgggtgccagtgtagaacatgc
 ggtctgcgagaacctgccctgccccaaagggtctgccagcttccgggaccagcagtgccaggcacacgaccgggtgagccccaaga
 agaaaggcctgctgacagccgtggtggtgacgataagccatgtgaactctactgctcgcccctcggaaggagtccccactgctggtg
 gccgacaggggtcctggacgggtacacctgcggggccctacgagactgatctctgctgcacggcaagtgccagaaaatcggtgtgac
 ggcatcatcgggtctgcagccaaagaggacagatgcggggtctgcagcggggacggcaagacctgccacttggtgaaggcgactt
 cagccacgccccggggacaggttatatcgaagctgccgtcattcctgctggagctcggaggatccgtgtggtggaggataaacctgcc
 cacagc ttctgggtaaaacacaaatgact

FIG. 4 Nucleic Acid Sequence of ADAMTS-J1.4 [SEQ ID NO: 4]

atgtgtgacggcgccctgctgcctccgctcgtcctgcccgtgctgctgctgctggttggggactggacccgggcacagctgtcggcgac
 gcggcgccgacgtggagggtgtcctccgtggcggtgctgccccgacgacgtgcacctgccgcccgtgcccgcagcccccgggc
 cccgacggcgcgacgccccgcacgccccagccgccccgcgccccggagagcgccctgctgctgcacctgccg
 gccttcgggcgcgacctgtacctcagctgccccgcacctgctgcttctgctcccgaggcttcgagggtggaggaggcgggcgggccc
 ggcgccgcccggccccgcgagctgtcttactcgggcccgtgtcctgcccacccccggctccctcgtctcgtcagcgctgccc
 gccgcccggcgctggttgccctcattcagcttgggcaggagcagggtgtaataccagccctcaacaactcccaggggccattcagtg
 gacgagaacatctgatcaggcgcaaatggtcctgacccccagcccttctgctgaggcccagagacctgagcagctctgaagttct
 aacagaaaagaagaagccgacgtggggcaggccttgcgggactggcgggagcgagggaacgctatccggctcaccagcgagc
 acacggtggagaccctggtggtggcgacgccgacatggtgcagtaccacggggccgaggctgccagagggtcatcctgaccgtc
 atgaacatggtatacaatatgttcagcaccagagcctggggattaaataacattcaagtaccaagctgtctgctacgacaacgt
 cccgctaagttgtccattgggcaccatggtgagcgggtccctggagagcttcgtcactggcagaacgaggagtatggaggagcgcgata
 cctcggcaataaccagggtcccggcggaaggacgacccgcccctggtggtgctgctgtgttgtgaccaggacagatttctgtgtac
 acaaagatgaaccgtgtgacactgttggaattgcttacttaggaggtgtgtgcagtgtgaaggaagtgtgtgcttgccgaagacaatg
 gtctcaatttgcccttaccatcgcccatgagctggggccacaacttgggcatgaaccacgacgatgaccactcatcttgctggtgaggt
 cccacatcatgtcaggagagtggtgaaaggccggaacccaagtgcacctcttggctcctcctgcagccgagatgacctgaaaacttc
 ctcaagtcaaaagtcagcacctgctgtagtacggaccccagaagccagcacacagtagcctcccgacaaagctgccgggcat
 gcactacagtgtccaaagagcagtgccagatcctgttggcatgaatgccaccttctgcagaaacatggagcatctaattgtgtgtgact
 gtggtgcctgtagaaggagacacatcctgcaagaccaagctggaccctcccctggatggcaccgagtggtggggcagacaagtgt
 gccgcgccggggagtgctgagcaagacgcccatcccgagcatgtggacggagactggagcccgtggggcgccctggagcatgt
 gcagccgaacatgtgggacgggagcccgttccggcagaggaaatgtgacaacccccccctgggctggaggcacacactgccc
 ggggtccagtgtagaacatgcggtctgcgagaacctgcccgtcccaagggtctgccagcttccgggaccagcagtgccaggcac
 acgacccggtgagcccaagaagaaggcctgctgacagccgtggtggtgacgataagccatgtgaactctactgctgcccctcg
 ggaaggagtccccactgctggtggcgacagggtcctggacggtacacctgcgggcccctacgagactgatctctgctgcacggca
 agtgccagaaaaatcggtgtgacggcatcatcggtgtgcagccaaagaggacagatcggggtctgcagcggggacggcaaga
 cctgccacttggtgaaggcgacttcagccacgccccggggacaggttatcgaagctgccgtcattcctgctggagctcggaggatc
 cgtgtggtggaggataaacctgcccacagcttctggtctcaaagactcgggtaagggtccatcaacagtactggaagatagagc
 tccccggagagttccagattgcaggcacaactgttcgctaigtgagaagggggtgtgggagaagatctctgccaagggaccaacca
 aactaccgctgcactgatggtgtgttattcacgaccaagattatggaaltcattatgaatacactgttctgtaaaccgactgcggaaa
 atcaaagcgaaccagaaaaccgcaggactcttgttcatctggaccacagcggctgggaagggtgcagtgtcagtgcgcgga
 ggggagcgcagaacatcgttctgttacaggtgtcaacaagacccaacttgggtgaacgacagtactgcctcaagcaagc
 cggccagagccccagggtccgaagggtgcaactgcacccctgccagtcacggtaa

FIG. 5 ADAMTS-J1.1 polypeptide [SEQ ID NO: 5]

mcdgallppvlvpvlllvwglpdtavgdadvevvpwrvrpdvhlpplpaapgprrrrrrtppaaprarpgerallhlpafgrdlyl
 qlrrdlrlsrgfeveeagaarrgrpaelfysgrvlghpgslvlsacgaagglvgliqlgqeqlvliqplnnsqgpfsgrehlrrkwsltsp
 saeaqrpeqlckvltekkkptwgrpsrdwrerrnairltsehtvetlvadadmvyhgaaqriltvmnmvynmfqhqsikiniq
 vtlvlrlrpaklsighhgerslesfchwqneeyggarylgnnqvpggkddpplvdaavfvtrtdfcvhkdepdvtgiaylggvcsakr
 kcvlaednglnlaftiahelghnlgmnhdhddhsscagrshimgewvkgpnpsdlwsscsrddlenflkskvstcllvtdprsqhtvrlp
 hklpgmhysaneqcqilfgmnatfcrnmehlmcaglwclvegdtscctklppldgtecgadkwcragecvsktpipehvdgdwsp
 wgawsmcsrtcgtgarfrqrkcdnpppgpggthcpgasvehavcenlpcpkglpsfrdqqcqhadrspkkkglltavvvddkpcely
 cspigkespllvadrldgtpcgpyetdlcvhgkcqkigcdgiisaakedrcgvcsdgdgktchlvgkdfshargtgyieaavipagarrir
 vvedkpahsfigktqmt

FIG. 6 ADAMTS-J1.2 polypeptide [SEQ ID NO: 6]

mcdgalppvlvpvlllvwglpdtavgdadvevvpwrvrpdvhlpplpaapgprrrrrprtpaaprarpgerallhlpafgrdlyl
qlrrdlrlsrgfeveeagaarrgrpaelfysgrvlghpgslvslsacgaagglvgliqlgqeqlvliqplnnsqgpfsgrehlirrkwsitpsp
saeaqrpeqlckvltekkkptwgrpsrdwrerrnairltsehtvetlvvadadmvqyhgaeeaaqrfltmnmvynmfqhqsigikiniq
vtklvllrqpaklsighhgerslesfchwqneeyggarylgnnqvpggkddpplvdaavfvtrtdfcvhkdepdvtgiaylggvc sakr
kcvlaednglnlaftiaheighnlgmnhddd hsscagrshimsgewvkg rnp s d l s w s s c s r d d l e n f n p g p g g t h c p g a s v e h a v
cenlpcpglpsfrdqqcah d r l s p k k k g l l t a v v d d k p c e l y c s p l g k e s p l l v a d r v l d g t p c g p y e t d l c v h g k c q k i g c d g i g s a
akedrcgvcsdgdktchlvgdfshar g t v k n d l c t k v s t c v m a e a v p k c f s c y i e a a v i p a g a r r i r v e d k p a h s f l g k t q m t

FIG. 7 ADAMTS-J1.3 polypeptide [SEQ ID NO: 7]

mcdgalppvlvpvllllvwgldpgtekkkptwgrpsrdwrernairltsehtvetlvvadadmvyhgaeaaqrfltmnmvynmfqh
 qslgikiniqvtklvllrqpaklsighhgerslesfchwqnkeyggarylgnnqvpggkddpplvdaavfvtrtdfcvhkdepcdtvgiayl
 ggvc sakrkc v laednglnlaftiahelghnlgmnhddd hsscagrshimsgewvkgrnpsdlswsscsrddlenflkskvstcllvtdp
 rsqhtvrlphklpgmhysaneqcqilfgmnatfcrnmehlmcaglwclvegdtscctklppldgtecgadkwcragecvsktpipeh
 vdgdwspwgawsmcsrtcgtgarfrqrkcdnpppgpggthcpgasvehavcenlpcpkglpsfrdqqcqahdrispkkkglltavvv
 ddkpcelycsplgkespllvadrldgtpcgpyetdlcvhgkcqkigcdgiisaakedrcgvcsdgdgktchlvkgdfshargtgyieaav
 ipagarrirvvedkpahsflgktqmt

FIG. 8 ADAMTS-J1.4 polypeptide [SEQ ID NO: 8]

mcdgallppvlvpvlllvwglpdtavgdadvevlpwrvrddvhlpplpaaagpprrrrprtppaaprarpgerallhlpafgrdlyl
 qlrrdlrlsrgfeveeagaarrgrpaelfysgrvlghpgslvsisacgaagglvgliqgqeqlvliqplnnsqgpfsgrehlirrkwsitpsp
 saeaqrpeqlckvitekktwgrplrdwrerrnairtsehtvetlvvadadmvyhgaaqrfltmnmvynmfqhqsigikiniqv
 tkvlrrqrpaklsighhggerslesfchwqneeyggarylgnnqvpggkddpplvdaavfvtrtdfcvhkdepcdtvgiaylggvcsakrk
 cvlaednglnlaftiahelghnlgmnhdddhsccagrshmsgewvkgrnpsdlwsscsrddlenflkskvstcllvtdprsqhtvrlph
 klpgmhysaneqcqilfgmnatfcrnmehlmcaglwclvegdtscctklppldgtecgadkwcragecvsktpipehvdgdwspw
 gawsmcsrtcgtagrfrqrkcdnpppgpggthcpgasvehavcenlpcpkglpsfrdqqcqhahrlspkkkglltavvddkpcelyc
 splgkespllvadvldgtpcgpyetdlcvhgkcqkigcdgiisaakedrcgvcsgdgtchlvgkdfshargtgyieaavipagarri
 vedkpahsfalkdsgkgsinsdwkielpgefqiagttvryvrrglwekisakgptklplhmvllfhdqdygiheyetvpvnrtanqsep
 ekpqdslfiwthsgwegcsvqcggertrivscrtivnktptlvndscpqasrpepqvrrcnlhpcqsr


FIG. 9 Partial cDNA sequence of ADAMTS-J1 [SEQ ID NO: 9]

```

ccccgccgagctgtgcttctactcgggcccgtgtgctcggccacccccggctccctcgtctcgtcagcgccctcggcgccgccggcgggcc
tggttgccctcattcagcttgggcaggagcaggtgctaaccagcccctcaacaactcccagggccattcagtgagcagagaacatctg
atcaggcgcaaatggccttgacccccagcccttctgctgagggcccagagacctgagcagctctgcaaggttcaacagaaaagaag
aagccgacgtggggcaggccttgcgggactggcgggagcggaggaaacgctatccggctcaccagcgagcacacgggtggagacc
ctgggtgggtggccgacgcccacatgggtcagtagccacggggccgaggctgccagaggttcacctgaccgtcatgaacatggtataca
atatgtttcagcaccagagcctggggattaaaataacattcaagtaccacagcttgctctgctacgacaacgtcccgtaagttgtccatt
gggcaccatggtagcggtccctggagagcttctgtcactggcagaacgaggagtatggaggagcgcgatacctcggcaataacca
gggtcccgcggggaaggacgacccgcccctggtagtgctgtgtgtgtgaccaggacagatttctgttacacaaagatgaaccgt
gtgacactgttgaattgcttacttaggaggtgtgtcagtgctaagaggaagtgtgtgcttgccgaagacaatggtctcaatttggccttta
ccatcgcccatgagctgggccacaacttgggcatgaaccacgacgatgacctcatcttgcgtggcagggtccacatcatgtcagg
agagtgggtgaaaggccggaaccaagtacacctcttggctcctcgtcagccgagatgaccttgaaaacttctcaagtcaaaagtca
gcacctgttgcctagtcacggaccccagaagccagcacacagtacgcctcccgccacaagctcgccgggcatgactacagtgcacac
gagcagtgccagatcctgttggcatgaatgccaccttctgcagaaacatggagcatctaattgtgtgctggactgtggtgacctgtagaag
gagacacatcctgcaagaccaagctggaccctcccctggatggcaccgagtggtggggcagacaagtggtgccgcgccccgggagtg
cgtgagcaagacgcccacccggagcatgtggacgggagactggagcccgtggggcgctggagcatgtgcagccgaacatgtggg
acgggagccccgttccggcagaggaaatgtgacaacccccccctgggcctggaggcacacactgccccgggtgccagtgtagaac
atgcggtctcgagaacctgcccctgccccaaaggtctgccagcttccgggaccagcagtgccaggcacacgacccggctgagcccc
aagaagaaaggcctgctgacagccgtggtggtgacgataagccatgtgaactctactgctcgccctcgggaaggagtccccactgc
tggtggccgacagggctcctggacggtacacctgcccggccctacgagactgatctctgctgcacggcaagtccagaaaatcggt
gtgacggcatcatcgggtctgcagccaaagaggacagatgcggggtctgcagcggggacggcaagacctgccacttggtagaggg
cgacttcagccacgccccgggggacaggttatatcgaagctgccgtcattcctgctggagctcggaggatccgtgtggtggaggataaac
ctgcccacagcttctgggtaaaaacacaaatgacttgactcaccattatgtgtgagaatcgatttgatgatcagcttggtaaattggtcag
tgtcaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

```


Figures 10A and 10B. Domain structure of ADAMTS-J1.1 and translated nucleic acid sequence. A) Diagram of ADAMTS-J1.1 showing the following domains and signature motifs (with amino acid numbers in parentheses): prodomain (1-223), furin cleavage site (220-223), metalloproteinase domain (224-449), Zn-binding motif (389-400), disintegrin domain (466-521), thrombospondin motif (546-609), two heparin-binding motifs (546-552 and 555-560), and spacer region (626-729). B) ADAMTS-J1.1 nucleotide sequence with translated amino acid sequence above.



```

+1 V L I Q P L N N S Q G P F S G R E H L I R R K W S L :
Prodomain
=====
461 GTGCTAATCC AGCCCTCAA CAACTCCCAG GGGCCATTCA GTGGACGAGA ACATCTGATC AGGCGCAAAT GGTCTTGGAC
CAGGATTAGG TCGGGGAGTT GTTGAGGGTC CCGGGTAAGT CACCTGCTCT TGTAGACTAG TCCGCGTTTA CCAGGAAGTC

+1 P S P S A E A Q R P E Q L C K V L T E K K K P T W G
Prodomain
=====
561 CCCCAGCCCT TCTGCTGAGG CCCAGAGACC TGAGCAGCTC TGCAAGGTTC TAACAGAAAA GAAGAAGCCG ACGTGGGGCA
GGGGTCGGGA AGACGACTCC GGGTCTCTGG ACTCGTCGAG ACGTTCCAAG ATTGTCTTTT CTCTCTCGGC TGCACCCCGT

+1 R P S R D W R E R R N A I R L T S E H T V E T L V V A
Furin Cleavage Site
=====
Prodomain Metalloproteinase Domain
=====
641 GGCCTTCGCG GGA CTGGCGG GAGCGGAGGA ACGCTATCCG GCTCACCAGC GAGCACACGG TGGAGACCCT GGTGGTGGCC
CCGGAAGCGC CCGTACCACC CTCGCTCCT TCGGATAGGC CGAGTGGTCG CTCGTGTGCC ACCTCTGGGA CCACCACCGG

+1 D A D M V Q Y H G A E A A Q R F I L T V M N M V Y N M
Metalloproteinase Domain
=====
721 GACGCCGACA TGGTGCACTA CCACGGGGCC GAGGCCGCCC AGAGGTTTCT CTTGACCGTC ATGAACATGG TATACAATAT
CTGCGGCTGT ACCACGTCAT GGTGCCCCGG TCCCGGCGGG TCTCCAAGTA GGA CTGGCAG TACTTGTACC ATATGTTATA

+1 F Q H Q S L G I K I N I Q V T K L V L L R Q R P A E
Metalloproteinase Domain
=====
801 GTTTCAGCAC CAGAGCTGG GGATTAAAT TAACATTCAA GTGACCAAGC TTGTCTGCT ACGACAAGT CCGGCTAAGT
CAAAGTCGTG GTCTCGGACC CCTAATTTTA ATTGTAAGT CACTGGTTCG AACAGGACGA TGCTGTTGCA GGGCGATTCA

+1 L S I G H H G E R S L E S F C H W Q N E E Y G G A R Y
Metalloproteinase Domain
=====
881 TGTCCATTGG GCACCATGGT GAGCGGTCCC TGGAGAGCTT CTGTCACTGG CAGAACGAGG AGTATGGAGG AGCGCGATAC
ACAGGTAACC CGTGGTACCA CTCGCCAGGG ACCTCTCGAA GACAGTGACC GTCTTGCTCC TCATACCTCC TCGCGCTATG

+1 L G N N Q V P G G K D D P P L V D A A V F V T R T D F
Metalloproteinase Domain
=====
961 CTCGGCAATA ACCAGGTTCC CGGCGGGAAG GACGACCCGC CCCTGGTGGG TGCTGCTGTG TTTGTGACCA GGACAGATT
GAGCCGTTAT TGGTCCAAGG GCCGCCCTTC CTGCTGGGCG GGGACCACCT ACGACGACAC AACACTGGT CCTGTCTAAA

+1 C V H K D E P C D T V G I A Y L G G V C S A K R K C
Metalloproteinase Domain
=====
1041 CTGTGTACAC AAAGATGAAC CGTGTGACAC TGTTGGAATT GCTTACTTAG GAGGTGTGTG CAGTGCTAAG AGGAAGTGTG
GACACATGTG TTTCTACTTG GCACACTGTG ACAACCTTAA CGAATGAATC CTCCACACAC GTCACGATTC TCCTTACAC

```

+1 V L A E D N G L N L A F T : A H E L G H N L G M N H C
Zinc-binding Motif:
=====

Metalloproteinase Domain
=====

1121 TGCTTGCCGA AGACAATGGT CTCAATTTGG CCTTTACCAT CGCCCATGAG CTGGGCCACA ACTTGGGCAT GAACCACGAC
ACGAACGGCT TCTGTTACCA GAGTTAAACC GGAAATGGTA GCGGGTACTC GACCCGGTGT TGAACCCGTA CTTGGTGCTG

+1 D D H S S C A G R S H I M S G E W V K G R N P S D L S
Metalloproteinase Domain
=====

1201 GATGACCACT CATCTTGCGC TGGCAGGTCC CACATCATGT CAGGAGAGTG GGTGAAAGGC CGGAACCCAA GTGACCTCTC
CTACTGGTGA GTAGAACGCG ACCGTCCAGG GTGTAGTACA GTCCTCTCAC CCACCTTCCG GCCTTGGGT CACTGGAGAG

+1 W S S C S R D D L E N F L K S K V S T C L L V T D P
Metalloproteinase Domain
=====

1281 TTGGTCCTCC TGCAGCCGAG ATGACCTTGA AAACCTCCTC AAGTCAAAAG TCAGCACCTG CTGTAGTGC ACGGACCCCA
AACCAGGAGG ACGTCGGCTC TACTGGAAT TTTGAAGGAG TTCAGTTTTC AGTCGTGGAC GAACGATCAG TGCTGGGGT

+1 R S Q H T V R L P H K L P G M H Y S A N E Q C Q I L F
Disintegrin Domain
=====

1361 GAAGCCAGCA CACAGTACGC CTCCCGCACA AGCTGCCGGG CATGCACTAC AGTGCCAACG AGCAGTGCCA GATCCTGTT
CTTCGGTCGT GTGTCATGCG GAGGSCGTGT TCGACGGCCC GTACGTGATG TCACGGTTGC TCGTCACGGT CTAGGACAAA

+1 G M N A T F C R N M E H L M C A G L W C L V E G D T S
Disintegrin Domain
=====

1441 GGCATGAATG CCACCTTCTG CAGAAACATG GAGCATCTAA TGTGTGCTGG ACTGTGGTGC CTGGTAGAAG GAGACACATC
CCGTACTTAC GGTGGAAGAC GTCTTTGTAC CTCGTAGATT ACACACGACC TGACACCACG GACCATCTTC CTCTGTGTAG

+1 C K T K L D P P L D G T E C G A D K W C R A G E C V
Disintegrin Domain
=====

1521 CTGCAAGACC AAGCTGGACC CTCCCCTGGA TGGCACCAG TGTGGGGCAG ACAAGTGGTG CCGCGCGGGG GAGTGCCTGA
GACGTTCTGG TTCGACCTGG GAGGGGACCT ACCGTGGCTC ACACCCCGTC TGTTCAACAC GGCAGCGCCC CTCACGCACT

+1 S K T P I P E H V D G D W S P W G A W S M C S R T C G
Heparin-binding Motif Heparin-binding Motif
=====

Thrombospondin Domain
=====

1601 GCAAGACGCC CATCCCGGAG CATGTGGACG GAGACTGGAG CCCGTGGGGC GCCTGGAGCA TGTGCAGCCG AACATGTGGG
CGTTCTGCGG GTAGGGCCTC GTACACCTGC CTCTGACCTC GGGCACCCCG CGGACCTCGT ACACGTGCGC TTGTACACCC

+1 T G A R F R Q R K C D N P P P G P G G T H C P G A S V
Thrombospondin Domain
=====

1681 ACGGGAGCCC GCTTCCGGCA GAGGAAATGT GACAACCCCC CCCCTGGGOC TGGAGGCACA CACTGCCCGG GTGCCAGTGT
TGCCCTCGGG CGAAGGCCGT CTCCTTTACA CTGTGGGGG GGGGACCCCG ACCTCCGTGT GTACGGGCC CACGGTCACA

+1 E H A V C E N L P C P K G L P S F R D Q Q C Q A H S
 Thrombospondin Domain.
 =====

1761 AGAACATGCG GTNTGCGAGA ACCTGCCCTG CCCCAAGGGT CTGCCCAGCT TCCGGGACCA GCAGTGCCAG GCACACGACC
TCTTGTACGC CANACGCTCT TGGACGGGAC GGGGTGCCA GACGGGTCGA AGGCCCTGGT CGTCACGGTC CGTGTGCTGC

+1 R L S F K K K G L L T A V V V D D K P C E L Y C S P L
 Spacer Region.
 =====

1841 GGCTGAGCCC CAAGAAGAAA GGCCTGCTGA CAGCCGTGGT GGTGACGAT AAGCCATGTG AACTCTACTG CTCGCCCCCTC
CCGACTCGGG GTTCTTCTTT CCGGACGACT GTCGGCACCA CCAACTGCTA TTCGGTACAC TTGAGATGAC GAGCGGGGAG

+1 G K E S P L L V A D R V L D G T P C G P Y E T D L C V
 Spacer Region.
 =====

1921 GGGAAAGGAGT CCCCACTGCT GGTGGCCGAC AGGGTCCTGG ACGGTACACC CTGCGGGCCC TACGAGACTG ATCTCTGCGT
CCCTTCTCTCA GGGGTGACGA CCACCGGCTG TCCAGGACC TGCCATGTGG GACGCCCGGG ATGCTCTGAC TAGAGACGCA

+1 H G K C Q K I G C D G I I G S A A K E D R C G V C S
 Spacer Region
 =====

2001 GCACGGCAAG TGCCAGAAAA TCGGCTGTGA CGGCATCATC GGGTCTGCAG CCAAAGAGGA CAGATGCGGG GTCTGCAGCG
CGTGCCGTTT ACGGTCTTTT AGCCGACACT GCCGTAGTAG CCCAGACGTC GGTTCCTCCT GTCTACGCCC CAGACGTCGC

+1 G D G K T C H L V K G D F S H A R G T G Y I E A A V I
 Spacer Region
 =====

2081 GGGACGGCAA GACCTGCCAC TTGGTGAAGG GCGACTTCAG CCACGCCCGG GGGACAGGTT ATATCGAAGC TGCCGTCATT
CCCTGCCGTT CTGGACGGTG AACCATTCC CGCTGAAGTC GGTGCGGGCC CCCTGTCCAA TATAGCTTCG ACGGCAGTAA

+1 P A G A R R I R V V E D K P A H S F L G K T Q M T
 Spacer Region
 =====

2161 CCTGCTGGAG CTCGGAGGAT CCGTGTGGTG GAGGATAAAC CTGCCACAG CTTTCTGGGT AAAACACAAA TGA
GGACGACCTC GAGCCTCCTA GGCACACCAC CTCCTATTG GACGGGTGTC GAAAGACCCA TTTGTGTTT ACTGA

FIG. 11




Fig. 12

Metalloproteinase Domain Alignment of TS-J1 v. ADAMTS Family

		Percent Homology	
		Sim	Ident
hADAMTS-4 (210-438)	241	46	36
hADAMTS-5 (AF142099)	(1)	45	30
hADAMTS-1 (AF060152)	(204)	43	29
hADAMTS-8 (AF060153)	(179)	48	33
hADAMTS-2 (AJ003125)	(174)	41	29
J1-MPD	(223)		
Consensus	(1)		
hADAMTS-4 (210-438)	301	63	48 (TS-4 v TS-5)
hADAMTS-5 (AF142099)	(7)		
hADAMTS-1 (AF060152)	(264)		
hADAMTS-8 (AF060153)	(239)		
hADAMTS-2 (AJ003125)	(218)		
J1-MPD	(263)		
Consensus	(8)		
hADAMTS-4 (210-438)	361		
hADAMTS-5 (AF142099)	(65)		
hADAMTS-1 (AF060152)	(322)		
hADAMTS-8 (AF060153)	(297)		
hADAMTS-2 (AJ003125)	(276)		
J1-MPD	(323)		
Consensus	(66)		
hADAMTS-4 (210-438)	421		
hADAMTS-5 (AF142099)	(112)		
hADAMTS-1 (AF060152)	(369)		
hADAMTS-8 (AF060153)	(344)		
hADAMTS-2 (AJ003125)	(323)		
J1-MPD	(371)		
Consensus	(124)		
hADAMTS-4 (210-438)	481		
hADAMTS-5 (AF142099)	(169)		
hADAMTS-1 (AF060152)	(426)		
hADAMTS-8 (AF060153)	(401)		
hADAMTS-2 (AJ003125)	(381)		
J1-MPD	(426)		
Consensus	(184)		
	(481)		

FIG 13 Expression of ADAMTS-J1 splice variants in HEK 293 cells

